0001387131-21-005719.txt : 20210517 0001387131-21-005719.hdr.sgml : 20210517 20210517131414 ACCESSION NUMBER: 0001387131-21-005719 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210517 DATE AS OF CHANGE: 20210517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NANOPHASE TECHNOLOGIES Corp CENTRAL INDEX KEY: 0000883107 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS PRIMARY METAL PRODUCTS [3390] IRS NUMBER: 363687863 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-22333 FILM NUMBER: 21929140 BUSINESS ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 BUSINESS PHONE: 6303231200 MAIL ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 FORMER COMPANY: FORMER CONFORMED NAME: NANOPHASE TECHNOLOGIES CORPORATION DATE OF NAME CHANGE: 19970305 10-Q 1 nanx-10q_033121.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended: March 31, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of
the Securities Exchange Act of 1934

For the transition period from to

Commission File Number: 000-22333

Nanophase Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware	36-3687863
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

1319 Marquette Drive, Romeoville, Illinois 60446

(Address of principal executive offices, and zip code)

Registrant’s telephone number, including area code: (630) 771-6708

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☐	Smaller reporting company ☑

	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

As of May 17, 2021, there were 48,336,877 shares outstanding of common stock, par value $.01, of the registrant.

NANOPHASE TECHNOLOGIES CORPORATION

QUARTER ENDED MARCH 31, 2021

INDEX

Page

PART I - FINANCIAL INFORMATION		3
Item 1.	Unaudited Consolidated Condensed Financial Statements	3
	Balance Sheets (Unaudited Consolidated Condensed) as of March 31, 2021 and December 31, 2020	3
	Statements of Operations (Unaudited Consolidated Condensed) for the three months ended March 31, 2021 and 2020	4
	Statements of Shareholders' Equity (Unaudited Consolidated Condensed) for the three months ended March 31, 2021 and 2020	5
	Statements of Cash Flows (Unaudited Consolidated Condensed) for the three months ended March 31, 2021 and 2020	6
	Notes to Unaudited Consolidated Condensed Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23
Item 4.	Controls and Procedures	23

PART II - OTHER INFORMATION		23
Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	24
Item 5.	Other Information	24
Item 6.	Exhibits	24

SIGNATURES

PART I - FINANCIAL INFORMATION

Item 1. Financial Statement

NANOPHASE TECHNOLOGIES CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited Consolidated Condensed)
(in thousands except share and per share data)


	March 31,			December 31,
ASSETS	2021			2020
Current assets:
Cash	$	1,819		$	957
Trade accounts receivable, less allowance for doubtful accounts of $9 for both March 31, 2021 and December 31, 2020		3,828			2,932
Inventories, net		5,001			4,340
Prepaid expenses and other current assets		653			606
Total current assets		11,301			8,835
Equipment and leasehold improvements, net		3,004			2,868
Operating leases, right of use		1,886			1,827
Other assets, net		10			10
Total assets	$	16,201		$	13,540
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Line of credit, bank	$	500		$	500
Line of credit, related party		3,365			2,155
Current portion of long-term debt, related party		500			500
Current portion of finance lease obligations		168			177
Current portion of operating lease obligations		477			431
Accounts payable		2,448			2,126
Deferred revenue		495			411
Accrued expenses		1,055			484
Total current liabilities		9,008			6,784

Long-term portion of finance lease obligations		73			110
Long-term portion of operating lease obligations		1,656			1,651
Long-term convertible loan, related party		1,164			1,097
PPP Loan (SBA)		952			952
Asset retirement obligations		216			214
Total long-term liabilities		4,061			4,024

Contingent liabilities		—			—
Shareholders’ equity:

Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding		—			—
Common stock, $.01 par value, 55,000,000 shares authorized; 38,221,292 shares issued and outstanding on March 31, 2021 and December 31, 2020, respectively		382			382
Additional paid-in capital		102,159			102,117
Accumulated deficit		(99,409	)		(99,767	)
Total Shareholders’ equity		3,132			2,732
	$	16,201		$	13,540

See Notes to Consolidated Condensed Financial Statements.

NANOPHASE TECHNOLOGIES CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited Consolidated Condensed)

(in thousands except share and per share data)

	Three months ended March 31,
	2021		2020
Revenue:
Product revenue	$	7,050	$	3,961
Other revenue		22		78
Total revenue		7,072		4,039

Cost of revenue		5,042		3,005
Gross profit		2,030		1,034

Operating expense:
Research and development expense		499		372
Selling, general and administrative expense		1,034		705
Income (loss) from operations		497		(43	)
Interest expense		139		124
Income (loss) before provision for income taxes		358		(167	)
Provisions for income taxes		-		-
Net Income (loss)	$	358	$	(167	)

Net income (loss) per share – basic	$	0.01	$	(0.00	)

Weighted average number of basic shares outstanding		38,221,292		38,136,792

Net income (loss) per share – diluted	$	0.01	$	(0.00	)

Weighted average number of diluted shares outstanding		39,811,292		38,136,792

See Notes to Consolidated Condensed Financial Statements.

NANOPHASE TECHNOLOGIES CORPORATION

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(Unaudited Consolidated Condensed)

(in thousands except share data)

	Preferred				Common				Additional Paid-in		Accumulated
Description	Shares		Amount		Shares		Amount		Capital		Deficit			Total
Balance on December 31, 2019		—	$	—		38,136,792	$	381	$	101,886	$	(100,756	)	$	1,511
Stock-based compensation		—		—						52					52
Net loss for the three months ended March 31, 2020		—		—								(167	)		(167	)
Balance on March 31, 2020		—	$	—		38,136,792	$	381	$	101,938	$	(100,923	)	$	1,396
Balance on December 31, 2020		—	$	—		38,221,292	$	382	$	102,117	$	(99,767	)	$	2,732
Stock-based compensation		—		—						42					42
Net Income for the three months ended March 31, 2021		—		—								358			358
Balance on March 31, 2021		—	$	—		38,221,292	$	382	$	102,159	$	(99,409	)	$	3,132

See Notes to Consolidated Condensed Financial Statements.

NANOPHASE TECHNOLOGIES CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited Consolidated Condensed)

	Three months ended March 31,
	2021			2020
	(in thousands)
Operating activities:
Net Income (loss)	$	358		$	(167	)
Adjustments to reconcile net income (loss) to cash used in operating activities:
Depreciation and amortization		101			86
Amortization of debt discount		67			67
Share-based compensation		42			52

Changes in assets and liabilities related to operations:
Trade accounts receivable		(896	)		(1,284	)
Inventories		(661	)		170
Prepaid expenses and other assets		(47	)		8
Accounts payable		253			(35	)
Accrued expenses		571			133
Deferred revenue		84			(207	)
Other long-term assets and liabilities		(9	)		(3	)
Net cash used in operating activities		(137	)		(1,180	)

Investing activities:
Acquisition of equipment and leasehold improvements		(166	)		(181	)
Net cash used in investing activities		(166	)		(181	)

Financing activities:
Principal payments on finance leases		(46	)		(58	)
Proceeds from line of credit, bank		500			500
Payments to line of credit, bank		(500	)		(500	)
Proceeds from line of credit, related party		6,500			3,260

Payments to line of credit, related party		(5,289	)		(2,084	)
Net cash provided by financing activities		1,165			1,118

Increase (decrease) in cash and cash equivalents		862			(243	)
Cash and cash equivalents at beginning of period		957			1,194
Cash and cash equivalents at end of period	$	1,819		$	951

Supplemental cash flow information:
Interest paid	$	51		$	57

Supplemental non-cash investing and financing activities:
Accounts payable incurred for the purchase of equipment and leasehold improvements	$	69		$	77

See Notes to Consolidated Condensed Financial Statements.

NANOPHASE TECHNOLOGIES CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited Consolidated Condensed)

(in thousands, except share and per share data or as otherwise noted herein)

(1) Basis of Presentation

The accompanying unaudited consolidated condensed interim financial statements of Nanophase Technologies Corporation (“Nanophase”, “Company”, “we”, “our”, or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair statement of our financial position and operating results for the interim periods presented. All statements include the results from both Nanophase and our wholly-owned subsidiary, Solesence, LLC (“Solésence,” or our “Solésence® subsidiary”). Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.

These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission.

(2)

Going Concern / Liquidity

We believe that cash from operations and cash on hand, in addition to unused borrowing capacity, which has recently been increased (see Note 7), may not be adequate to fund our operating plans through the next twelve months. We are working to reduce these risks and the results of the Company in this regard have improved markedly, but some of this is dependent on several things over which we have limited control. The significant revenue growth that we have experienced has required additional investment in both working capital and capital equipment. This has constrained liquidity and made cash management a top priority. Generally, our growth has required significant additional investment in working capital. To support our growth and reduce costs, we also intend to invest in additional capital equipment through 2021 and in 2022. Given these issues, and other commercial realities, we are monitoring the additional working capital demands that this could create as we continue to execute on our Solésence growth strategy. The timing of cash flows is critical. If cash generated from operations is not materially consistent with our plans, we believe that we may need to seek additional funding to address working capital demands. This uncertainty has caused us to be unable to assert that, for the next twelve months, we have enough current cash and guaranteed access to financing to fund operations, and to continue with our current growth strategy in terms of investment in capital equipment and in operating expenses related to Solésence, without securing additional financing.

These circumstances raise substantial doubt as to the Company’s ability to operate as a going concern under U.S. GAAP. The accompanying financial statements have been prepared on a going concern basis in accordance with U.S. GAAP. As such, no adjustments have been made to the consolidated financial statements for the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue operating as a going concern.

We believe that we will be able to secure additional financing if needed, but we do not have any additional financing commitments in place as of today. However, we may not be able to secure additional financing in a timely manner under commercially reasonable terms, or at all. If we are unable to secure additional financing, the operations of the Company might need to be curtailed to a certain degree, and we would need to delay capital expenditures related to our Solésence growth strategy, which could impede growth, and impact cost savings anticipated in 2021 and 2022.

(3) Description of Business

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence subsidiary”), is focused in various beauty- and life-science markets. Skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy. We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of markets in skin care, including for use in sunscreens as active ingredients and as fully developed prestige skin care products, marketed and sold through our Solésence subsidiary. In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably COVID-19, has become a critical use of our technology. Additionally, we continue to sell products in markets for architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications— all of which, along with medical diagnostics, fall into the advanced materials product category.

We target markets, primarily related to skin health products and ingredients, and diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements and market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands. Over the past few years, we have expanded our marketing efforts for our Solésence products and are seeing more customers responding to our successful products being sold into their markets. Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. In addition, through the creation of our Solésence subsidiary, we utilize this particle surface treatment to manufacture and sell fully developed solutions to targeted customers in the skin care industry, in addition to the ingredients we have traditionally sold in the personal care area.

Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products.

(4) Revenues

Revenues are generally recognized at a point in time, typically when control of the promised goods is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods.

(5) Earnings Per Share

Options to purchase approximately 1,590,000 shares of common stock that were outstanding as of March 31, 2021 were included in the computation of earnings per share for the three months ended March 31, 2021. Options to purchase approximately 1,000 shares of common stock that were outstanding as of March 31, 2020 were not included in the computation of earnings per share for three months ended March 31, 2020, as the impact of such shares are anti-dilutive.

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

	Three Months Ended March 31,
	2021		2020
Numerator: (in Thousands)
Net income (loss)	$	358	$	(167	)

Denominator:
Weighted average number of basic common shares outstanding		38,221,292		38,136,792
Weighted average additional shares assuming conversion of in-the-money stock options to common shares		1,590,000		—
Weighted average number of diluted common shares outstanding		39,811,292		38,136,792

Basic earnings per common share:
Net income (loss) per share – basic	$	0.01	$	(0.00	)
Diluted earnings per common share:
Net income (loss) per share – diluted	$	0.01	$	(0.00	)

(6) Financial Instruments

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with the promissory note with no related borrowings described in Note 7, any borrowings on the working capital line of credit from Libertyville Bank and Trust, and any borrowings on the working capital line of credit, along with the term loan from Beachcorp, LLC, and the promissory note payable associated with the convertible loan described in Note 7 below. The fair values of all financial instruments were not materially different from their carrying values.

There were no financial instruments adjusted to fair value on March 31, 2021 and December 31, 2020.

(7) Notes and Line of Credit

During July 2014 we entered into a bank-issued letter of credit and related promissory note for up to $30 in borrowings to support our obligations under our facility lease agreement. No borrowings have been incurred under this promissory note. Should any borrowings occur in the future, the interest rate would be the prime rate plus 1%, with the bank having the right to “set off” or apply unpaid balances against our checking account if we fail to meet our obligations under any borrowings under the note. It is our intention to renew this note annually, for as long as we need to do so pursuant to the terms of our facility lease agreement. Because there were no amounts outstanding on the note at any time during 2021 or 2020, we have recorded no related liability on our consolidated balance sheet.

We have a Business Loan Agreement with Libertyville Bank and Trust Company, a Wintrust Community Bank (“Libertyville”). Under the Business Loan Agreement, Libertyville will provide a maximum of (i) $500 or (ii) two times the sum of (a) 75% our eligible accounts receivables and (b) our cash deposited with Libertyville, whichever is less, of revolving credit to us, collateralized by a senior priority lien on our accounts receivable, inventory, equipment, general intangibles, and fixtures. Interest is payable monthly on any advances at a floating interest rate of the prime rate at the time plus 1%. We must have $500 in cash, inclusive of the borrowed amount, at Libertyville on the date of any advance. Advances may only occur at the beginning or end of a fiscal quarter and must be repaid in full within five business days of the advance. Amounts due under the Business Loan Agreement were paid in full on April 4, 2021, as required. It is management’s expectation that the Business Loan Agreement will be renewed in May 2021.

On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. Beachcorp, LLC is managed by Bradford T. Whitmore, who, together with his affiliate Grace Investments, Ltd., beneficially owned approximately 63% of the outstanding shares of our common stock as of March 31, 2021. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, accruing from the date of such advance and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “Revolver Facility”), and to extend the maturity date, with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and with all principal and accrued interest due March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extends the maturities of both the Term Loan and the Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expands the limit on the Revolver Facility from $2,000 to $2,750. On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expands the limit on the Revolver Facility from $2,750 to $4,000 and extends the maturities of both the Term Loan and the Revolver Facility to March 31, 2022. On April 21, 2021, the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expands the limit on the Revolver Facility from $4,000 to $6,000, extends its maturity to March 31, 2023, and reduces interest on outstanding borrowings from the prime rate plus 3%, with an 8.25% minimum floor, to the prime rate plus 2%, with no minimum rate floor. Additionally, the Fourth Amendment increased the amount of the Term Loan from $500 to $1,000, and its fixed interest rate was reduced from 8.25% per year to 5.25% per year. The maturity date of the Term Loan remains March 31, 2022. The Term Loan and Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the Business Loan Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the Revolver Facility.

On November 20, 2019, we entered into a 2% Secured Convertible Promissory Note with Bradford T. Whitmore in the principal amount of $2,000 (the “Convertible Note”). The principal amount is payable in a single payment on May 15, 2024 (the “Maturity Date”). The principal amount of the Convertible Note accrues interest at the rate of 2.0% per year, which interest is payable semi-annually on the 15th day of May and November, commencing on May 15, 2020. The principal amount and, at the holder’s option, accrued interest under the Convertible Note is convertible at the holder’s option into additional shares of the Company’s common stock in whole or in part and from time to time up to the Maturity Date at a conversion price of $0.20 per share. The convertible note contains a beneficial conversion feature since the Company’s stock was trading at $0.32 per share on the date the Company entered into the agreement. The intrinsic value of the beneficial conversion feature was $1.2 million on November 20, 2019 and is recorded as a discount on the convertible note. The discount will be accreted to the convertible note over the life of the note using the straight-line method. The balance on the convertible note was $1,164, net of a discount of $836 at March 31, 2021, and $1,097, net of a discount of $903 at December 31, 2020. Mr. Whitmore chose to exercise his conversion rights effective May 7, 2021, requesting that any accrued interest be paid him in the form of shares, as allowed in the Convertible Note. This will result in the accelerated recognition of the discount on the Convertible Note, to be recognized as interest expense in the second quarter of 2021.

On April 17, 2020, we entered into a Promissory Note (the “PPP Note”), dated as of April 16, 2020, in favor of Libertyville in the principal amount of $952 for our loan under the Paycheck Protection Program (“PPP”). The Company may apply for forgiveness of the amount due on the PPP Note in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part. The principal amount of the PPP Note accrues interest at the rate of 1.00% per year. The Company will be required to pay any unforgiven principal and interest under the PPP Note in eighteen equal monthly installments, with the first payment originally being due on November 17, 2020 and continuing on the same day of each subsequent month until April 17, 2022. Management applied for loan forgiveness in February 2021. Payment of principal and interest have been postponed due to the request for loan forgiveness, and recognition of such will be dependent upon the outcome of the Company’s request under the PPP. On March 31, 2021, the balance under the PPP note remained $952.

On March 31, 2021, the balance on the term loan was $500, the balance on the Revolver Facility was $3,365, and the balance on the Convertible Note was $2,000. For the three months ended March 31, 2021, and 2020, there was $131 and $111, respectively, in interest expense relating to these credit facilities held by Beachcorp, LLC and Bradford T. Whitmore. The accrued interest expense balance on these related party credit facilities amounted to $36, and $20, at March 31, 2021 and December 31, 2020, respectively. The obligations under the Convertible Note are secured by a security interest in all of the Company’s personal property pursuant to a Commercial Security Agreement among Mr. Whitmore, the Company and Solésence, LLC, the Company’s sole subsidiary. Given that Beachcorp, LLC is an affiliate of Mr. Whitmore, this amounts to all of this interest being owed to a related party. On March 31, 2021 borrowings were within the credit agreement limit with an additional $388 available. The balance of borrowing base, loan amount, and any excess payments required over the available borrowing base will change as frequently as daily, given the operational nature of the elements of the Revolver Facility.

(8) Inventories

Inventories consist of the following:

	March 31, 2021			December 31, 2020
Raw materials	$	3,883		$	2,825
Finished goods		1,148			1,545
		5,031			4,370
Allowance for excess inventory quantities		(30	)		(30	)
	$	5,001		$	4,340

(9) Leases

The Company's operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company's leases include one or more options to renew or terminate the lease at the Company's discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term.

As of March 31, 2021, the operating lease right-of-use “ROU” asset had a balance of $1,886 which is included in the “Operating lease right-of-use assets” line item of these condensed consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $477 and $1,656, respectively. As of December 31, 2020, the ROU asset had a balance of $1,827 which is included in the “Operating lease right-of-use assets” line item of these condensed consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $431 and $1,651, respectively. These are included in the “Current portion of operating lease obligations” and “Long-term operating lease obligations, net of current portion” line items of these condensed consolidated financial statements. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.

The office leases contain variable lease payments which consist primarily of rent escalations based on an established index or rate and taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor.

Quantitative information regarding the Company’s leases is as follows:

	Three Months Ended March 31, 2021		Three Months Ended March 31, 2020
Components of lease cost
Finance lease cost components:
Amortization of finance lease assets	$	14	$	17
Interest on finance lease liabilities		6		11
Total finance lease costs		20		28
Operating lease cost components:
Operating lease cost		144		140
Variable lease cost		31		27
Short-term lease cost		10		2
Total operating lease costs		185		169

Total lease cost	$	205	$	197

Supplemental cash flow information related to leases is as follows for the period ended March 31:

	2021			2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflow from operating leases	$	183		$	171

Weighted-average remaining lease term-finance leases (in years)		1.3			1.7
Weighted-average remaining lease term-operating leases (in years)		3.1			2.7
Weighted-average discount rate-finance leases		10.1	%		9.3	%
Weighted-average discount rate-operating leases		14.2	%		14.6	%

The future maturities of the Company’s finance and operating leases as of March 31, 2021 is as follows:

	Finance Leases			Operating Leases			Total
2021	$	144		$	559		$	703
2022		109			761			870
2023		5			747			752
2024		—			636			636
2025		—			42			42
2026 and thereafter		—			2			2
Total payments	$	258		$	2,747		$	3,005
Less amounts representing interest		(17	)		(614	)		(631	)
Total minimum payments required:	$	241		$	2,133		$	2,374

The future maturities of the Company’s finance and operating leases as of March 31, 2020 were as follows:

	Finance Leases			Operating Leases			Total
2020	$	189		$	506		$	695
2021		196			687			883
2022		109			705			814
2023		5			690			695
2024		—			580			580
2025 and thereafter		—			—			—
Total payments	$	499		$	3,168		$	3,667
Less amounts representing interest		(51	)		(862	)		(913	)
Total minimum payments required:	$	448		$	2,306		$	2,754

(10) Share-Based Compensation

We follow FASB ASC Topic 718, Compensation – Stock Compensation, in which compensation expense is recognized only for share-based payments expected to vest. We recognized compensation expense related to stock options of $42 and $52 for each of the three-month periods ended March 31, 2021 and 2020, respectively.

As of March 31, 2021, there was approximately $206 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under our stock option plans. That cost is expected to be recognized over a remaining weighted-average period of 1.7 years.

Stock Options and Stock Grants

No stock options were exercised during the three months ended March 31, 2021, or March 31, 2020. No stock options were granted during the three months ended March 31, 2021, or March 31, 2020. During the three months ended March 31, 2021, 35,000 stock options expired, and no stock options were forfeited, compared to 241,000 stock options which expired, and 140,000 stock options which were forfeited during the same period in 2020. We had 3,411,000 stock options outstanding at a weighted average exercise price of $0.57 on March 31, 2021, compared to 3,332,000 stock options outstanding at a weighted average exercise price of $0.63 on March 31, 2020.

(11) Significant Customers and Contingencies

Revenue from five customers constituted approximately 24%, 20%, 17%, 15% and 10%, respectively, of our total revenue for the three months ended March 31, 2021. Amounts included in accounts receivable on March 31, 2021 relating to these five customers were approximately $837, $812, $476, $855, and $390, respectively. Revenue from these five customers constituted approximately 0%, 46%, 15%, 4% and 15%, respectively, of our total revenue for the three months ended March 31, 2020. Amounts included in accounts receivable on March 31, 2020 relating to these five customers were approximately $0, $896, $31, $180, and $593, respectively. The loss of one of these significant customers, a significant decrease in revenue from one or more of these customers, or the failure to attract new customers could have a material adverse effect on our business, results of operations and financial condition.

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements, certain other obligations and/or certain financial condition covenants. The financial condition covenants in one of our supply agreements with BASF “trigger” a technology transfer right (license and equipment sale at BASF’s option) in the event (a) that earnings for the twelve-month period ending with our most recently published quarterly financial statements are less than zero and our cash, cash equivalents and certain investments are less than $500, or (b) of an acceleration of any debt maturity having a principal amount of more than $10 million. There are certain minimum finished goods inventory requirements with the new amendment to the supply agreement. This agreement also requires Nanophase to maintain certain finished goods inventory levels as “safety stock,” beginning in the first quarter of 2019, and increasing through the third quarter of 2019 to a negotiated level based on agreed demand metrics, in order to maintain the $500 non-cash component discussed above. After September 30, 2019, should our safety stock fall below the prescribed amount of material, the quarter-end cash requirement would revert to $1,000 in cash, cash equivalents, and certain investments. The safety stock requirement may be adjusted upon mutual agreement. The Company met its safety stock requirements at March 31, 2021.

Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value, or the greater of 30% of the original book value of such equipment, and any associated upgrades to it.

We believe that cash from operations and cash on hand, in addition to unused borrowing capacity, may not be adequate to fund our operating plans through 2021. If a triggering event were to occur and BASF elected to proceed with the license and related equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of some of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us. Finally, any shortfall in capital needed to operate the business as management intends, including with respect to avoiding this triggering event as described above, may result in a curtailment of certain activities or anticipated investments.

We expect to expend resources on research, development, and product testing, and in expanding current capacity or capability for new business. In addition, we may incur significant costs in preparing, filing, prosecuting, maintaining, and enforcing our patents and other proprietary rights. We may need additional financing if we were to lose an existing customer or suffer a significant decrease in revenue from one or more of our customers or because of currently unknown capital requirements, new regulatory requirements, or the need to meet the cash requirements discussed above to avoid a triggering event under our BASF agreement. Given our expected continuing growth in our Solésence business, we may also have temporary working capital demands that we cannot fund with existing capital, while remaining in compliance with the covenants included in our BASF agreement described above. We expect our single biggest financing need in 2021, as it was in 2020, will relate to the funding of our working capital, which has grown significantly to support the growth of our business. In the likely event that we will need to seek additional financing, we may seek funding through public or private financing and through contracts with governmental entities or other companies. Additional financing may not be available on acceptable terms or at all, and any such additional financing could be dilutive to our shareholders. If we are unable to obtain adequate funds, we may be required to delay, scale-back or eliminate some of our manufacturing and marketing operations or we may need to obtain funds through arrangements on less favorable terms. Such circumstances raise doubt as to our ability to continue as a going concern. If we obtain funding on unfavorable terms, we may be required to relinquish rights to some of our intellectual property.

(12) Business Segmentation and Geographical Distribution

Revenue from international sources approximated $1,285 and $304 for the three months ended March 31, 2021 and 2020, respectively. All this revenue was product revenue.

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue streams into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence®. The revenues for the three months ended March 31, 2021 and 2020, respectively, by category, are as follows:

Product Category	2021		2020
Personal Care Ingredients	$	1,395	$	1,932
Advanced Materials		1,378		584
Solésence^®		4,299		1,523
Total Revenue	$	7,072	$	4,039

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Nanophase is a skin health focused company whose primary products are fully developed prestige skin care formulations, marketed and sold through our Solésence subsidiary, enabled by our proprietary Active Pharmaceutical Ingredients (“APIs”) which are also marketed as APIs for sale to manufacturers of other types of skin health products, including sunscreens and daily care products. In terms of the balance of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, which are used in testing for various viruses, most notably COVID-19. Additionally, we continue to sell products in markets for architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications— all of which, along with medical diagnostics, currently fall into the advanced materials product category.

Leveraging a platform of integrated patented and proprietary technologies, we create products with unique performance to enhance consumers’ health and well-being. We offer soup-to-nuts production, from engineered materials, formulation development, and finished product development to commercial manufacturing and packaging capabilities. Our expertise in materials engineering allows us to effectively coat and disperse materials on a nano and “non-nano” scale for use in a variety of markets in skin health, including for use in sunscreens as Active Pharmaceutical Ingredients (“APIs”) and as fully developed prestige skin care products, marketed and sold through our Solésence beauty science subsidiary. We believe that we have developed technological advantages with respect to our APIs sold for use as ingredients, while our Solésence beauty science technologies lead to enhanced efficacy in our finished products.

We have seen current conditions significantly increase demand for our medical diagnostics materials. Polymerase Chain Reaction (“PCR”) testing for various viruses, most notably SARS-CoV-2 (“COVID-19”), has become a critical use of our technology in the life science space. While we cannot predict whether the increased demand for our medical diagnostic materials used in COVID-19 testing will continue, we believe that our deep expertise in materials science has created advantages that enable performance in certain tests that may not be achievable through other materials. Outside of life science, we continue to sell advanced materials for use in legacy applications, all of which, along with medical diagnostics, currently fall into the advanced materials product category.

Given our technological position, in addition to the historical market acceptance of our APIs for use in skin health products and sunscreens, rapidly growing sales for our suite of Solésence® finished products, and growing use of our diagnostic materials in aiding the fight to curb the spread of COVID-19 and other viruses, we have reoriented our Company strategy. We are seeing unprecedented demand in both beauty science and life science areas. The markets for both have shown an appetite for what we are producing, and management believes that this growth is happening now due to a confluence of our technology, market conditions that favor what we produce, and our expanded expertise in these areas.

Nanophase, and Solésence, is now focusing our combined business-, ingredient-, and product-development capabilities on products with unique performance that enhance consumers’ wellbeing through beauty science and life science applications — in skin health and medical diagnostics, respectively. While we will continue to produce and sell materials to our other advanced materials customers, it is not our strategic focus. We may develop additional technologies, or find unique applications outside of our core markets in the future, but to maximize the use of our resources today, we plan on expanding efforts in areas where we have proven we can deliver innovation and growth.

Results of Operations

Total revenue increased to $7,072,000 for the three months ended March 31, 2021, compared to $4,039,000 for the same period in 2020.

A substantial majority of our revenue for both periods was from our five largest customers, in particular, sales to our largest customer in skin care and sunscreen applications, medical diagnostics, and now finished skin health products marketed through our Solésence subsidiary. Product revenue, the primary component of our total revenue, increased to $7,050,000 three months ended March 31, 2021, compared to $3,961,000 during the same period of 2020. This increase was due to continued growth in the adoption of our Solésence® products and our medical diagnostics materials, offset by a decrease in revenue from our largest customer in our personal care ingredients business.

Current Significant Customers

	Three months ended March 31,
	2021			2020
Largest Personal Care Customer		20	%		46	%
Medical Diagnostics Customer		15	%		4	%
Solésence Customer – 3		24	%		0	%
Solésence Customer – 2		17	%		15	%
Solésence Customer – 1		10	%		15	%
Significant Customer Total		86	%		80	%

Other revenue decreased to $22,000 for the three months ended March 31, 2021, compared to $78,000 for the three months ended March 31, 2020. Other revenue is typically comprised primarily of developmental or licensing fees. For the three months ended March 31, 2020, other revenue included $65,000 to development fees recognized for the Company’s work on behalf of a customer relating to new personal care ingredients.

Cost of revenue generally includes costs associated with commercial production and customer development arrangements. Cost of revenue increased to $5,042,000 for the three months ended March 31, 2021, compared to $3,005,000 for the same period in 2020. The increase in cost of revenue was primarily driven by increased volume and price inflation on materials and manufacturing inefficiencies related to Solésence® product launches. While we typically pass through costs to our customers, we sometimes cannot pass through 100% of pricing increases on raw materials, and even with pass throughs, our gross margin percentage is negatively impacted by higher material costs. We expect to continue new advanced material development relating to personal care ingredients and for our formulated Solésence® products during 2021 and beyond.

At current revenue levels we have generated a positive gross margin, though margins can be impeded by the cyclicality of our demand, often leading to the Company not having enough revenue to efficiently absorb manufacturing overhead that is required to work with current customers and expected future customers. Another issue relating to demand cyclicality is that we have seen our lack of burst capacity creating strains, in terms of people and costs, when new product launches occur at the same time demand from previously launched products comes to play. We believe that our current fixed manufacturing cost structure is sufficient to support higher levels of revenue volume on a level basis, and are currently working to expand burst capacity to allow us to utilize our resources more efficiently. The extent to which margins grow, as a percentage of total revenue, will be dependent upon revenue mix, revenue volume, our ability to continue to cut costs and pass commodity market-driven raw materials increases on to customers, and the speed and efficiency with which we are able to scale up production for our Solésence products. We expect that, as product revenue volume increases, our fixed manufacturing costs will be more efficiently absorbed, which should lead to increased margins as we grow. We expect to continue to focus on reducing controllable variable product manufacturing costs, with potential variability related to the commodity metals markets, but may or may not realize absolute dollar gross margin growth through 2021 and beyond, dependent upon the factors discussed above.

Research and development expense, which includes all expenses relating to the technology and advanced engineering groups, primarily consists of costs associated with the development or acquisition of new finished product formulations for skin care, new product applications for our skin care ingredients, advancement of our medical diagnostics ingredient knowledge, and the cost of enhancing our manufacturing processes. As an example, we are currently focusing the bulk of our resources on developing new product formulations, and related new technologies, as we expand marketing and sales efforts relating to our Solésence products. This work has led to several new products and additional potential new products. Our efforts in research and development, cosmetic formulating, process engineering and advanced engineering groups are focused in three major areas: 1) application development for our products; 2) creating or obtaining additional core materials technologies and/or materials that have the capability to serve multiple skin health-related markets; and 3) continuing to improve our core technologies to improve manufacturing operations and reduce costs.

Research and development expense increased, as planned, to $499,000 for the three months ended March 31, 2021, compared to $372,000 for the same period in 2020. The primary reasons for this increase were related to increases in staffing and compensation, offset by reductions in professional fees and outside product testing and evaluation costs related to our Solésence® products. We expect quarterly research and development expense to remain at, or slightly above, current levels, for the balance of 2021.

Selling, general and administrative expense increased, as planned, to $1,034,000 for the three months ended March 31, 2021, compared to $705,000 for the same period in 2020. Much of this was attributed to increases in staffing and compensation. We expect selling, general, and administrative expense to remain at current levels for the balance of 2021.

Interest expense was $139,000 for the three months ended March 31, 2021, compared to $124,000 for the same period in 2020. This primarily includes interest on our revolving line of credit for working capital funding, cash, and discount-related interest expense on our $2,000,000 Convertible Note, along with finance leases and term loans supporting some of our equipment.

Inflation

We believe inflation has not had a material effect on our operations or financial position. However, supplier price increases and wage and benefit inflation, both of which represent a significant component of our costs of operations, may have a material effect on our operations and financial position in 2021 and beyond if we are unable to pass through any applicable increases under our present contracts or through to our markets in general.

Liquidity and Capital Resources

Our cash and cash equivalents amounted to $1,819,000 on March 31, 2021, compared to $957,000 on December 31, 2020 and $951,000 on March 31, 2020. The net cash used in our operating activities was $137,000 for the three months ended March 31, 2021, compared to $1,180,000 for the same period in 2020. The net use of cash during both periods was driven primarily by a significant increase in accounts receivable at the end of the period. Net cash used in investing activities was $166,000 during the three months ended March 31, 2021, compared to $181,000 for the three months ended March 31, 2020. Capital expenditures amounted to $166,000 and $181,000 for the three months ended March 31, 2021 and 2020, respectively. Net cash provided by financing activities was $1,165,000 during the three months ended March 31, 2021, compared to $1,118,000 for the three months ended March 31, 2020. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extends the maturities of both the Term Loan and the Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expands the limit on the Revolver Facility from $2,000,000 to $2,750,000. On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expands the limit on the Revolver Facility from $2,750,000 to $4,000,000 and extends the maturities of both the Term Loan and the Revolver Facility to March 31, 2022. On April 21, 2021, the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expands the limit on the Revolver Facility from $4,000,000 to $6,000,000, extends its maturity to March 31, 2023, and reduces interest on outstanding borrowings from the prime rate plus 3%, with an 8.25% minimum floor, to the prime rate plus 2%, with no minimum rate floor. Additionally, the Fourth Amendment increased the amount of the Term Loan from $500,000 to $1,000,000, and its fixed interest rate was reduced from 8.25% per year to 5.25% per year. The maturity date of the Term Loan remains March 31, 2022.

We paid $46,000 for principal on finance lease obligations during the three months ended March 31, 2021 compared to $58,000 in the same period in 2020. The balance of the line of credit with Libertyville was $500,000 for both March 31, 2021 and December 31, 2020. In each instance, the line of credit was repaid during the month following the end of the reporting period. This line of credit expired on April 4, 2021. Management expects this line of credit to be renewed in May 2021. During the three months ending March 31, 2021, we drew $6,500,000, of which $5,289,000 was repaid under the Master Agreement. The net borrowings for the three months ended March 31, 2021 was $1,211,000. During the three months ending March 31, 2020, we drew $3,260,000, of which $2,084,000 was repaid under the Master Agreement. The net borrowings for the three months ended March 31, 2020 was $1,176,000. Accretion related to the Secured Convertible Promissory Note to Bradford T. Whitmore was $67,000 for both March 31, 2021 and 2020. The balance of this long-term convertible loan was $1,164,000 and $1,097,000 at March 31, 2021, and at December 31, 2020, respectively. Mr. Whitmore chose to exercise his conversion rights effective May 7, 2021, requesting that any accrued interest be paid him in the form of shares, as allowed in the Convertible Note. This will result in the accelerated recognition of the discount on the Convertible Note, to be recognized as interest expense in the second quarter of 2021.

On April 17, 2020, we received a loan of $952,000 from Libertyville under the Paycheck Protection Program (“PPP”). Under the PPP, the Company may apply for forgiveness of the amount due on the loan in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the Loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. Although management believes that the Company expended the proceeds of the PPP loan principally for forgivable purposes under the CARES Act, no assurance can be provided that the Company will obtain forgiveness of the PPP loan in whole or in part. The Company applied for PPP forgiveness during the first quarter of 2021.

Our supply agreements with our largest customer, BASF, contain certain financial covenants which could potentially impact our liquidity. The most restrictive financial covenants under these agreements require that we maintain a minimum of $1,000,000 in certain current assets; which may be composed of no less than $500,000 cash, cash equivalents, and certain investments, no more than a combined $500,000 of certain related inventory, of which no more than $250,000 can be raw material, and certain receivables, and that we not have the acceleration of any debt maturity having a principal amount of more than $10 million, in order to avoid triggering the customer’s potential right to transfer certain technology and equipment to that customer at a contractually-defined price. We had approximately $1,819,000 in cash on March 31, 2021, with $500,000 borrowings on our Line of Credit. This supply agreement and its covenants are more fully described in Note 11, and our line of credit is more fully described in Note 7, to our Financial Statements in Part I, Item 1 of this Form 10-Q.

We believe that cash from operations and cash on hand, in addition to unused borrowing capacity, which has recently been increased (see Note 7 to the Financial Statements), may not be adequate to fund our operating plans through 2021. We are working to reduce these risks, but some of this is dependent on several things over which we have limited control. We have seen an increase in sales of our Solésence products through 2020, which we expect to continue in 2021. If that does continue, we will require additional investment in working capital. Given these issues, and other commercial realities, we are monitoring the additional working capital demands that this could create as we continue to execute on our Solésence growth strategy. The timing of cash flows is critical. If cash generated from operations is not materially consistent with our plans, we believe that we may need to seek additional funding to address working capital demands. This uncertainty has caused us to be unable to assert that, for the next twelve months, we have enough current cash and guaranteed access to financing to fund operations, and to continue with our current growth strategy in terms of investment in capital equipment and in operating expenses related to Solésence, without securing additional financing. We believe that we will be able to secure additional financing if needed, but we do not have any additional financing commitments in place as of today. However, we may not be able to secure additional financing in a timely manner under commercially reasonable terms, or at all. If we are unable to secure additional financing, the operations of the Company might need to be curtailed to a certain degree, and we would need to delay capital expenditures related to our Solésence growth strategy, which could impede growth later in 2021 and 2022.

Our actual future capital requirements in 2021 and beyond will depend on many factors, including customer acceptance of our current and potential finished Solésence products, APIs sold as ingredients in to the skin health markets, medical diagnostics ingredients, and other engineered materials, applications, and products, continued progress in research and development activities and product testing programs, the magnitude of these activities and programs, and the costs necessary to increase and expand our manufacturing capabilities and to market and sell these products and ingredients. Other important issues that will drive future capital requirements will be the development of new markets and new customers as well as the potential for significant unplanned growth with existing customers. Depending on the success of certain projects, we expect that capital spending relating to currently known capital needs during the balance of 2021 will be between $1,400,000 and $2,000,000, to be funded by profit from operations, and our existing loans and lines of credit. If those projects are delayed or ultimately prove unsuccessful, or if we fail to be able to support the additional cost of funding them in the near term, we expect our capital expenditures may fall below the lower end of the range. Similarly, substantial success in business development projects may cause the actual 2021 capital investment to exceed the top of this range.

In the likely event that we will need to seek additional financing, such additional financing may not be available on acceptable terms or even at all, and any such additional financing could be dilutive to our shareholders. Such financing could be necessitated by such things as the loss of an existing customer; a significant decrease in revenue from one or more of our customers; temporary working capital demands resulting from our expected growth in our Solésence business that we cannot fund with existing capital; currently unknown capital requirements considering the factors described above; new regulatory requirements that are outside our control; the need to meet previously discussed cash requirements to avoid a triggering event under our BASF agreement; or various other circumstances coming to pass that we currently do not anticipate. The failure to have access to sufficient capital to fund our business plans may result in a curtailment or other change in those plans, and under such circumstances, this raises doubt as to our ability to continue as a going concern under U.S. GAAP.

On December 31, 2020, we had a net operating loss carryforward of approximately $67 million for income tax purposes. Because the Company may have experienced “ownership changes” within the meaning of the U.S. Internal Revenue Code (“IRC”) in connection with its various prior equity offerings, future utilization of this carryforward may be subject to certain limitations as defined by the IRC. If not utilized, $63 million of this loss carryforward will expire between 2021 and 2037. Given changes to the IRC, net operating loss carryforwards generated after January 1, 2018 do not expire, therefore, $5 million in net operating losses generated since January 1, 2018 do not expire.

Off−Balance Sheet Arrangements

We have not created, and are not party to, any special-purpose or off-balance sheet entities for the purposes of raising capital, incurring debt or operating our business. We do not have any off-balance sheet arrangements or relationships with entities that are not consolidated into our financial statements that are reasonably likely to materially affect our liquidity or the availability of capital resources.

As more fully described in Note 7 to our Financial Statements, in Part I, Item I of this Form 10-Q, during 2014 we entered into a letter of credit and promissory note for up to $30,000 supporting our obligations under our facility lease agreement. No borrowings have been incurred under this promissory note.

Safe Harbor Provision

We want to provide investors with more meaningful and useful information. As a result, this Quarterly Report on Form 10-Q (the "Form 10-Q") contains and incorporates by reference certain "forward-looking statements", as defined in Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements reflect our current expectations of the future results of our operations, performance, and achievements. Forward-looking statements are covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We have tried, wherever possible, to identify these statements by using words such as “anticipates”, “believes”, “estimates”, “expects”, “plans”, “intends” and similar expressions. These statements reflect management’s current beliefs and are based on information now available to it. Accordingly, these statements are subject to certain risks, uncertainties and contingencies that could cause our actual results, performance, or achievements in 2021 and beyond to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties and factors include, without limitation: our ability to be consistently profitable despite the losses we have incurred since our incorporation; a decision by a customer to cancel a purchase order or supply agreement in light of our dependence on a limited number of key customers; the terms of our supply agreements with BASF which could trigger a requirement to transfer technology and/or sell equipment to that customer; our potential inability to obtain working capital when needed on acceptable terms or at all; our ability to obtain materials at costs we can pass through to our customers, including Rare Earth elements, specifically cerium oxide, as well as high purity zinc; uncertain demand for, and acceptance of, our Solésence products, and our advanced materials; our manufacturing capacity and product mix flexibility in light of customer demand; our limited marketing experience, including with our suite of Solésence products; changes in development and distribution relationships; the impact of competitive products and technologies; our dependence on patents and protection of proprietary information; our ability to maintain an appropriate electronic trading venue for our securities; the impact of any potential new governmental regulations, especially any new governmental regulations focusing on the processing, handling, storage or sale of nanomaterials, that could be difficult to respond to or costly to comply with; business interruptions due to unexpected events or public health crises, including viral pandemics such as COVID-19; and the resolution of litigation or other legal proceedings in which we may become involved. In addition, our forward-looking statements could be affected by general industry and market conditions and growth rates. Readers of this Quarterly Report on Form 10-Q should not place undue reliance on any forward-looking statements. Except as required by federal securities laws, we undertake no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for a smaller reporting company.

Item 4. Controls and Procedures

Disclosure controls

We are responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports filed by us under the Exchange Act is: (a) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and (b) accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosures. It should be noted that in designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and that our management necessarily was required to apply its judgment regarding the design of our disclosure controls and procedures. As of the end of the period covered by this report, we conducted an evaluation, under the supervision (and with the participation) of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at reaching that level of reasonable assurance.

Internal control over financial reporting

The Company’s management, including the CEO (who is also currently acting as both the Company’s principal executive officer and the Company’s principal financial officer), confirm that there was no change in the Company’s internal control over financial reporting during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any pending legal proceedings or claims that we believe will result in a material adverse effect on our business, financial condition, or operating results.

Item 1A. Risk Factors

Not required for a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

	Exhibit 31.1	Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act.

	Exhibit 31.2	Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act.

	Exhibit 32	Certification of the Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350.

	Exhibit 101	The following materials from Nanophase Technologies Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, formatted in XBRL (Extensible Business Reporting Language): (1) the Balance Sheets, (2) the Statements of Operations, (3) the Statements of Shareholders Equity, (4) the Statements of Cash Flows, and (5) the Notes to Unaudited Consolidated Condensed Financial Statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NANOPHASE TECHNOLOGIES CORPORATION

Date: May 17, 2021	By:	/s/ JESS A. JANKOWSKI
		Jess A. Jankowski
		President and Chief Executive Officer
		(principal executive officer, and principal financial officer)

EX-31.1 2 ex31-1.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Nanophase Technologies Corporation 10-Q

Exhibit 31.1

Certification of the Chief Executive Officer

Pursuant to

Rules 13a-14(a) and 15d-14(a) under the Exchange Act

I, Jess A. Jankowski, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Nanophase Technologies Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 17, 2021

	/s/ JESS A. JANKOWSKI
	Jess A. Jankowski
	(principal executive officer, and principal financial officer)

EX-31.2 3 ex31-2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Nanophase Technologies Corporation 10-Q

Exhibit 31.2

Certification of the Principal Financial Officer

Pursuant to

Rules 13a-14(a) and 15d-14(a) under the Exchange Act

I, Jess Jankowski, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Nanophase Technologies Corporation;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 17, 2021

	/s/ JESS A. JANKOWSKI
	Jess A. Jankowski
	(principal executive officer, and principal financial officer)

EX-32 4 ex32.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

Nanophase Technologies Corporation 10-Q

Exhibit 32

Certification Pursuant to 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

In connection with this quarterly report of Nanophase Technologies Corporation (the “Company”) on Form 10-Q for the quarter ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jess A. Jankowski, Chief Executive Officer, and acting as Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to our knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 17, 2021

	/s/ JESS A. JANKOWSKI
	Jess A. Jankowski
	Chief Executive Officer
	(principal executive officer, and principal financial officer)

EX-101.INS 5 nanx-20210331.xml XBRL INSTANCE FILE 0000883107 2021-01-01 2021-03-31 0000883107 2021-05-17 0000883107 2021-03-31 0000883107 2020-12-31 0000883107 2020-01-01 2020-03-31 0000883107 us-gaap:ProductMember 2021-01-01 2021-03-31 0000883107 us-gaap:ProductMember 2020-01-01 2020-03-31 0000883107 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-03-31 0000883107 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-03-31 0000883107 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0000883107 us-gaap:PreferredStockMember 2019-12-31 0000883107 us-gaap:PreferredStockMember 2020-03-31 0000883107 us-gaap:CommonStockMember 2019-12-31 0000883107 us-gaap:CommonStockMember 2020-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000883107 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000883107 us-gaap:RetainedEarningsMember 2019-12-31 0000883107 us-gaap:RetainedEarningsMember 2020-03-31 0000883107 2019-12-31 0000883107 2020-03-31 0000883107 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000883107 us-gaap:PreferredStockMember 2020-12-31 0000883107 us-gaap:PreferredStockMember 2021-03-31 0000883107 us-gaap:CommonStockMember 2020-12-31 0000883107 us-gaap:CommonStockMember 2021-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000883107 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000883107 us-gaap:RetainedEarningsMember 2020-12-31 0000883107 us-gaap:RetainedEarningsMember 2021-03-31 0000883107 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0000883107 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000883107 us-gaap:EmployeeStockOptionMember 2021-03-31 0000883107 us-gaap:EmployeeStockOptionMember 2020-03-31 0000883107 us-gaap:SupplyCommitmentMember 2021-03-31 0000883107 us-gaap:SupplyCommitmentMember srt:MinimumMember 2021-03-31 0000883107 us-gaap:SupplyCommitmentMember srt:MaximumMember 2021-01-01 2021-03-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2021-01-01 2021-03-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFiveMember 2021-01-01 2021-03-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2020-01-01 2020-03-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFiveMember 2020-01-01 2020-03-31 0000883107 nanx:CustomerFourMember 2021-03-31 0000883107 nanx:CustomerFiveMember 2021-03-31 0000883107 nanx:CustomerFourMember 2020-03-31 0000883107 nanx:CustomerFiveMember 2020-03-31 0000883107 us-gaap:ManufacturedProductOtherMember 2021-01-01 2021-03-31 0000883107 us-gaap:ManufacturedProductOtherMember 2020-01-01 2020-03-31 0000883107 us-gaap:NonUsMember 2021-01-01 2021-03-31 0000883107 us-gaap:NonUsMember 2020-01-01 2020-03-31 0000883107 nanx:AdvancedMaterialsMember 2021-01-01 2021-03-31 0000883107 nanx:AdvancedMaterialsMember 2020-01-01 2020-03-31 0000883107 nanx:SolesenceMember 2021-01-01 2021-03-31 0000883107 nanx:SolesenceMember 2020-01-01 2020-03-31 0000883107 nanx:CustomerThreeMember 2020-03-31 0000883107 nanx:CustomerThreeMember 2021-03-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2021-01-01 2021-03-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2020-01-01 2020-03-31 0000883107 nanx:CustomerOneMember 2020-03-31 0000883107 nanx:CustomerOneMember 2021-03-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2020-01-01 2020-03-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2021-01-01 2021-03-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2021-01-01 2021-03-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2020-01-01 2020-03-31 0000883107 nanx:CustomerTwoMember 2021-03-31 0000883107 nanx:CustomerTwoMember 2020-03-31 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember 2019-03-21 2019-03-22 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember 2019-03-22 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2018-11-15 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2018-11-15 2018-11-16 0000883107 us-gaap:LetterOfCreditMember 2014-07-01 2014-07-31 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2018-11-16 0000883107 us-gaap:LetterOfCreditMember 2014-07-31 0000883107 nanx:FirstAmendmentMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BeachcorpLLCMember 2020-03-22 2020-03-23 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2019-11-19 2019-11-20 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2019-11-20 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2021-03-31 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2020-12-31 0000883107 nanx:RelatedPartyCreditFacilitiesMember 2021-01-01 2021-03-31 0000883107 nanx:RelatedPartyCreditFacilitiesMember 2020-01-01 2020-03-31 0000883107 nanx:SecondAmendmentMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2020-09-08 0000883107 nanx:ThirdAmendmentMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2020-12-23 0000883107 nanx:FourthAmendmentMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2021-04-21 0000883107 nanx:FourthAmendmentMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2021-04-20 2021-04-21 0000883107 nanx:PromissoryNoteMember nanx:LibertyvilleMember 2020-04-17 0000883107 nanx:PromissoryNoteMember nanx:LibertyvilleMember 2020-04-16 2020-04-17 0000883107 nanx:FourthAmendmentMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2021-04-21 0000883107 us-gaap:SupplyCommitmentMember srt:MaximumMember 2021-03-31 0000883107 us-gaap:SupplyCommitmentMember srt:MinimumMember 2019-09-30 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember srt:MinimumMember 2018-11-16 0000883107 nanx:FourthAmendmentMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2021-04-20 2021-04-21 0000883107 nanx:TermLoanMember nanx:BeachcorpLLCMember 2021-03-31 0000883107 us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2021-03-31 0000883107 nanx:RelatedPartyCreditFacilitiesMember 2021-03-31 0000883107 nanx:RelatedPartyCreditFacilitiesMember 2020-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure nanx:Number NANOPHASE TECHNOLOGIES Corp 0000883107 10-Q false 2021-03-31 000-22333 DE --12-31 Yes Yes true Non-accelerated Filer false false 48336877 Q1 2021

16201000

13540000

10000

1886000

1827000

3004000

2868000

11301000

8835000

653000

606000

5001000

4340000

3828000

2932000

855000

390000

180000

593000

31000

476000

837000

812000

896000

1819000

957000

9008000

6784000

1055000

484000

495000

411000

2448000

2126000

477000

431000

168000

177000

500000

3365000

2155000

500000

4061000

4024000

216000

214000

952000

1164000

1097000

1656000

1651000

73000

110000

16201000

13540000

3132000

2732000

381000

101886000

101938000

-100756000

-100923000

1511000

1396000

382000

102117000

102159000

-99767000

-99409000

-99767000

102159000

102117000

382000

9000

0.01

24088

0.01

55000000

38221292

7072000

4039000

7050000

3961000

22000

78000

1395000

1932000

1378000

584000

4299000

1523000

2030000

1034000

5042000

3005000

499000

372000

0.01

-0.00

358000

-167000

358000

-167000

139000

124000

131000

111000

497000

-43000

1034000

705000

38136792

38221292

42000

52000

42000

52000

67000

101000

86000

-137000

-1180000

9000

3000

84000

-207000

571000

133000

253000

-35000

47000

-8000

661000

-170000

896000

1284000

-166000

-181000

166000

181000

1165000

1118000

5289000

2084000

6500000

3260000

500000

46000

58000

1819000

957000

1194000

951000

862000

-243000

51000

57000

69000

77000

1590000

3883000

2825000

1148000

1545000

500000

5031000

4370000

30000

14000

17000

6000

11000

20000 28000

144000

140000

31000

27000

10000

2000

185000

169000

205000

197000

183000

171000

P1Y3M19D

P1Y8M12D

P3Y1M6D

P2Y8M12D

0.101

0.093

0.142

0.146

559000

506000

761000

687000

747000

705000

636000

690000

42000

580000

2000

2747000

3168000

614000

862000

2133000

2306000

144000

189000

109000

196000

5000

109000

5000

258000

499000

17000

51000

241000

448000

703000 695000 870000 883000 752000 814000 636000 695000 42000 580000 2000 3005000 3667000 631000 913000 2374000 2754000

42000

52000

206000

P1Y8M12D

35000

241000

140000

3411000

3332000

0.57

0.63

5 5

0.15

0.10

0.04

0.15

0.17

0.15

0.00

0.24

0.20

0.46

1285000

304000

38221292

38136792

0.01

-0.00

39811292

38136792

1.15 0.30

30000

0.01

0.03

0.01

0.02

Prime rate

500000

2000000

2750000

4000000

6000000

1000000

500000

2021-05-04

2020-03-31

2023-03-31

0.0825

0.02

0.01

0.0525

0.0825

2020-12-31

2021-03-31

2022-03-31

0.63

0.20

0.32

0.75

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended March 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Numerator: (in Thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">358</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(167</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Denominator:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Weighted average number of basic common shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">38,221,292</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">38,136,792</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,590,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Weighted average number of diluted common shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">39,811,292</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">38,136,792</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Basic earnings per common share:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net income (loss) per share – basic</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Diluted earnings per common share:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net income (loss) per share – diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr></table>

(8) Inventories   Inventories consist of the following:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 65%; text-align: left">Raw materials</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">3,883</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">2,825</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,148</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,545</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,031</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,370</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Allowance for excess inventory quantities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(30</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(30</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,001</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,340</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Inventories consist of the following:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 65%; text-align: left">Raw materials</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">3,883</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">2,825</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,148</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,545</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,031</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,370</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Allowance for excess inventory quantities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(30</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(30</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,001</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,340</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The future maturities of the Company’s finance and operating leases as of March 31, 2021 is as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; text-align: left">2021</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">144</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">559</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">703</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">761</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">870</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">752</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">636</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">636</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026 and thereafter</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total payments</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">258</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,005</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less amounts representing interest</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(17</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(614</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(631</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum payments required:</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,133</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,374</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The future maturities of the Company’s finance and operating leases as of March 31, 2020 were as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Finance Leases</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Operating Leases</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: left">2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">189</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">506</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">695</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2021</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">196</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">687</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">109</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">705</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">814</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2023</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">690</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">695</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">580</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">580</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025 and thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total payments</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">499</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,168</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less amounts representing interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(51</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(862</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(913</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total minimum payments required:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">448</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,306</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,754</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

1000

500000

1000000

10000000

2000000

952000

interest is payable semi-annually on the 15th day of May and November

eighteen equal monthly installments

2020-05-15

2020-11-17

1200000

836000

903000

1164000

1097000

2000000

952000

500000

3365000

36000

20000

388000

(1) Basis of Presentation   The accompanying unaudited consolidated condensed interim financial statements of Nanophase Technologies Corporation (“Nanophase”, “Company”, “we”, “our”, or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair statement of our financial position and operating results for the interim periods presented. All statements include the results from both Nanophase and our wholly-owned subsidiary, Solesence, LLC (“Solésence,” or our “Solésence® subsidiary”). Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.   These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">(2)</td> <td style="text-align: justify">Going Concern / Liquidity</td></tr> </table>   We believe that cash from operations and cash on hand, in addition to unused borrowing capacity, which has recently been increased (see Note 7), may not be adequate to fund our operating plans through the next twelve months. We are working to reduce these risks and the results of the Company in this regard have improved markedly, but some of this is dependent on several things over which we have limited control. The significant revenue growth that we have experienced has required additional investment in both working capital and capital equipment. This has constrained liquidity and made cash management a top priority. Generally, our growth has required significant additional investment in working capital. To support our growth and reduce costs, we also intend to invest in additional capital equipment through 2021 and in 2022. Given these issues, and other commercial realities, we are monitoring the additional working capital demands that this could create as we continue to execute on our Solésence growth strategy. The timing of cash flows is critical. If cash generated from operations is not materially consistent with our plans, we believe that we may need to seek additional funding to address working capital demands. This uncertainty has caused us to be unable to assert that, for the next twelve months, we have enough current cash and guaranteed access to financing to fund operations, and to continue with our current growth strategy in terms of investment in capital equipment and in operating expenses related to Solésence, without securing additional financing.   These circumstances raise substantial doubt as to the Company’s ability to operate as a going concern under U.S. GAAP. The accompanying financial statements have been prepared on a going concern basis in accordance with U.S. GAAP. As such, no adjustments have been made to the consolidated financial statements for the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue operating as a going concern.   We believe that we will be able to secure additional financing if needed, but we do not have any additional financing commitments in place as of today. However, we may not be able to secure additional financing in a timely manner under commercially reasonable terms, or at all. If we are unable to secure additional financing, the operations of the Company might need to be curtailed to a certain degree, and we would need to delay capital expenditures related to our Solésence growth strategy, which could impede growth, and impact cost savings anticipated in 2021 and 2022.

(3) Description of Business   Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence subsidiary”), is focused in various beauty- and life-science markets.  Skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of markets in skin care, including for use in sunscreens as active ingredients and as fully developed prestige skin care products, marketed and sold through our Solésence subsidiary.  In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably COVID-19, has become a critical use of our technology.  Additionally, we continue to sell products in markets for architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications— all of which, along with medical diagnostics, fall into the advanced materials product category.    We target markets, primarily related to skin health products and ingredients, and diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions.  We traditionally work closely with current customers in these target markets to identify their material and performance requirements and market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands. Over the past few years, we have expanded our marketing efforts for our Solésence products and are seeing more customers responding to our successful products being sold into their markets.  Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. In addition, through the creation of our Solésence subsidiary, we utilize this particle surface treatment to manufacture and sell fully developed solutions to targeted customers in the skin care industry, in addition to the ingredients we have traditionally sold in the personal care area.   Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.   While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products.

(4) Revenues   Revenues are generally recognized at a point in time, typically when control of the promised goods is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods.

(5) Earnings Per Share   Options to purchase approximately 1,590,000 shares of common stock that were outstanding as of March 31, 2021 were included in the computation of earnings per share for the three months ended March 31, 2021.  Options to purchase approximately 1,000 shares of common stock that were outstanding as of March 31, 2020 were not included in the computation of earnings per share for three months ended March 31, 2020, as the impact of such shares are anti-dilutive.   Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended March 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Numerator: (in Thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">358</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(167</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Denominator:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Weighted average number of basic common shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">38,221,292</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">38,136,792</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,590,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Weighted average number of diluted common shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">39,811,292</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">38,136,792</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Basic earnings per common share:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net income (loss) per share – basic</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Diluted earnings per common share:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net income (loss) per share – diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr></table>

(6) Financial Instruments   We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.   Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with the promissory note with no related borrowings described in Note 7, any borrowings on the working capital line of credit from Libertyville Bank and Trust, and any borrowings on the working capital line of credit, along with the term loan from Beachcorp, LLC, and the promissory note payable associated with the convertible loan described in Note 7 below. The fair values of all financial instruments were not materially different from their carrying values.   There were no financial instruments adjusted to fair value on March 31, 2021 and December 31, 2020.

(7) Notes and Line of Credit   During July 2014 we entered into a bank-issued letter of credit and related promissory note for up to $30 in borrowings to support our obligations under our facility lease agreement. No borrowings have been incurred under this promissory note. Should any borrowings occur in the future, the interest rate would be the prime rate plus 1%, with the bank having the right to “set off” or apply unpaid balances against our checking account if we fail to meet our obligations under any borrowings under the note. It is our intention to renew this note annually, for as long as we need to do so pursuant to the terms of our facility lease agreement. Because there were no amounts outstanding on the note at any time during 2021 or 2020, we have recorded no related liability on our consolidated balance sheet.   We have a Business Loan Agreement with Libertyville Bank and Trust Company, a Wintrust Community Bank (“Libertyville”). Under the Business Loan Agreement, Libertyville will provide a maximum of (i) $500 or (ii) two times the sum of (a) 75% our eligible accounts receivables and (b) our cash deposited with Libertyville, whichever is less, of revolving credit to us, collateralized by a senior priority lien on our accounts receivable, inventory, equipment, general intangibles, and fixtures. Interest is payable monthly on any advances at a floating interest rate of the prime rate at the time plus 1%. We must have $500 in cash, inclusive of the borrowed amount, at Libertyville on the date of any advance. Advances may only occur at the beginning or end of a fiscal quarter and must be repaid in full within five business days of the advance. Amounts due under the Business Loan Agreement were paid in full on April 4, 2021, as required.  It is management’s expectation that the Business Loan Agreement will be renewed in May 2021.   On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. Beachcorp, LLC is managed by Bradford T. Whitmore, who, together with his affiliate Grace Investments, Ltd., beneficially owned approximately 63% of the outstanding shares of our common stock as of March 31, 2021. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, accruing from the date of such advance and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “Revolver Facility”), and to extend the maturity date, with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and with all principal and accrued interest due March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extends the maturities of both the Term Loan and the Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expands the limit on the Revolver Facility from $2,000 to $2,750.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expands the limit on the Revolver Facility from $2,750 to $4,000 and extends the maturities of both the Term Loan and the Revolver Facility to March 31, 2022. On April 21, 2021, the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expands the limit on the Revolver Facility from $4,000 to $6,000, extends its maturity to March 31, 2023, and reduces interest on outstanding borrowings from the prime rate plus 3%, with an 8.25% minimum floor, to the prime rate plus 2%, with no minimum rate floor. Additionally, the Fourth Amendment increased the amount of the Term Loan from $500 to $1,000, and its fixed interest rate was reduced from 8.25% per year to 5.25% per year. The maturity date of the Term Loan remains March 31, 2022. The Term Loan and Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the Business Loan Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the Revolver Facility.   On November 20, 2019, we entered into a 2% Secured Convertible Promissory Note with Bradford T. Whitmore in the principal amount of $2,000 (the “Convertible Note”). The principal amount is payable in a single payment on May 15, 2024 (the “Maturity Date”). The principal amount of the Convertible Note accrues interest at the rate of 2.0% per year, which interest is payable semi-annually on the 15th day of May and November, commencing on May 15, 2020. The principal amount and, at the holder’s option, accrued interest under the Convertible Note is convertible at the holder’s option into additional shares of the Company’s common stock in whole or in part and from time to time up to the Maturity Date at a conversion price of $0.20 per share. The convertible note contains a beneficial conversion feature since the Company’s stock was trading at $0.32 per share on the date the Company entered into the agreement. The intrinsic value of the beneficial conversion feature was $1.2 million on November 20, 2019 and is recorded as a discount on the convertible note. The discount will be accreted to the convertible note over the life of the note using the straight-line method. The balance on the convertible note was $1,164, net of a discount of $836 at March 31, 2021, and $1,097, net of a discount of $903 at December 31, 2020. Mr. Whitmore chose to exercise his conversion rights effective May 7, 2021, requesting that any accrued interest be paid him in the form of shares, as allowed in the Convertible Note. This will result in the accelerated recognition of the discount on the Convertible Note, to be recognized as interest expense in the second quarter of 2021.   On April 17, 2020, we entered into a Promissory Note (the “PPP Note”), dated as of April 16, 2020, in favor of Libertyville in the principal amount of $952 for our loan under the Paycheck Protection Program (“PPP”).  The Company may apply for forgiveness of the amount due on the PPP Note in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part.    The principal amount of the PPP Note accrues interest at the rate of 1.00% per year.  The Company will be required to pay any unforgiven principal and interest under the PPP Note in eighteen equal monthly installments, with the first payment originally being due on November 17, 2020 and continuing on the same day of each subsequent month until April 17, 2022.  Management applied for loan forgiveness in February 2021.  Payment of principal and interest have been postponed due to the request for loan forgiveness, and recognition of such will be dependent upon the outcome of the Company’s request under the PPP.  On March 31, 2021, the balance under the PPP note remained $952.   On March 31, 2021, the balance on the term loan was $500, the balance on the Revolver Facility was $3,365, and the balance on the Convertible Note was $2,000. For the three months ended March 31, 2021, and 2020, there was $131 and $111, respectively, in interest expense relating to these credit facilities held by Beachcorp, LLC and Bradford T. Whitmore. The accrued interest expense balance on these related party credit facilities amounted to $36, and $20, at March 31, 2021 and December 31, 2020, respectively. The obligations under the Convertible Note are secured by a security interest in all of the Company’s personal property pursuant to a Commercial Security Agreement among Mr. Whitmore, the Company and Solésence, LLC, the Company’s sole subsidiary. Given that Beachcorp, LLC is an affiliate of Mr. Whitmore, this amounts to all of this interest being owed to a related party. On March 31, 2021 borrowings were within the credit agreement limit with an additional $388 available. The balance of borrowing base, loan amount, and any excess payments required over the available borrowing base will change as frequently as daily, given the operational nature of the elements of the Revolver Facility.

(10) Share-Based Compensation   We follow FASB ASC Topic 718, Compensation – Stock Compensation, in which compensation expense is recognized only for share-based payments expected to vest. We recognized compensation expense related to stock options of $42 and $52 for each of the three-month periods ended March 31, 2021 and 2020, respectively.   As of March 31, 2021, there was approximately $206 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under our stock option plans. That cost is expected to be recognized over a remaining weighted-average period of 1.7 years.   Stock Options and Stock Grants   No stock options were exercised during the three months ended March 31, 2021, or March 31, 2020. No stock options were granted during the three months ended March 31, 2021, or March 31, 2020. During the three months ended March 31, 2021, 35,000 stock options expired, and no stock options were forfeited, compared to 241,000 stock options which expired, and 140,000 stock options which were forfeited during the same period in 2020. We had 3,411,000 stock options outstanding at a weighted average exercise price of $0.57 on March 31, 2021, compared to 3,332,000 stock options outstanding at a weighted average exercise price of $0.63 on March 31, 2020.

(11) Significant Customers and Contingencies   Revenue from five customers constituted approximately 24%, 20%, 17%, 15% and 10%, respectively, of our total revenue for the three months ended March 31, 2021. Amounts included in accounts receivable on March 31, 2021 relating to these five customers were approximately $837, $812, $476, $855, and $390, respectively. Revenue from these five customers constituted approximately 0%, 46%, 15%, 4% and 15%, respectively, of our total revenue for the three months ended March 31, 2020. Amounts included in accounts receivable on March 31, 2020 relating to these five customers were approximately $0, $896, $31, $180, and $593, respectively. The loss of one of these significant customers, a significant decrease in revenue from one or more of these customers, or the failure to attract new customers could have a material adverse effect on our business, results of operations and financial condition.   We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements, certain other obligations and/or certain financial condition covenants. The financial condition covenants in one of our supply agreements with BASF “trigger” a technology transfer right (license and equipment sale at BASF’s option) in the event (a) that earnings for the twelve-month period ending with our most recently published quarterly financial statements are less than zero and our cash, cash equivalents and certain investments are less than $500, or (b) of an acceleration of any debt maturity having a principal amount of more than $10 million. There are certain minimum finished goods inventory requirements with the new amendment to the supply agreement. This agreement also requires Nanophase to maintain certain finished goods inventory levels as “safety stock,” beginning in the first quarter of 2019, and increasing through the third quarter of 2019 to a negotiated level based on agreed demand metrics, in order to maintain the $500 non-cash component discussed above. After September 30, 2019, should our safety stock fall below the prescribed amount of material, the quarter-end cash requirement would revert to $1,000 in cash, cash equivalents, and certain investments. The safety stock requirement may be adjusted upon mutual agreement. The Company met its safety stock requirements at March 31, 2021.   Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value, or the greater of 30% of the original book value of such equipment, and any associated upgrades to it.   We believe that cash from operations and cash on hand, in addition to unused borrowing capacity, may not be adequate to fund our operating plans through 2021. If a triggering event were to occur and BASF elected to proceed with the license and related equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of some of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us. Finally, any shortfall in capital needed to operate the business as management intends, including with respect to avoiding this triggering event as described above, may result in a curtailment of certain activities or anticipated investments.   We expect to expend resources on research, development, and product testing, and in expanding current capacity or capability for new business. In addition, we may incur significant costs in preparing, filing, prosecuting, maintaining, and enforcing our patents and other proprietary rights. We may need additional financing if we were to lose an existing customer or suffer a significant decrease in revenue from one or more of our customers or because of currently unknown capital requirements, new regulatory requirements, or the need to meet the cash requirements discussed above to avoid a triggering event under our BASF agreement. Given our expected continuing growth in our Solésence business, we may also have temporary working capital demands that we cannot fund with existing capital, while remaining in compliance with the covenants included in our BASF agreement described above. We expect our single biggest financing need in 2021, as it was in 2020, will relate to the funding of our working capital, which has grown significantly to support the growth of our business. In the likely event that we will need to seek additional financing, we may seek funding through public or private financing and through contracts with governmental entities or other companies. Additional financing may not be available on acceptable terms or at all, and any such additional financing could be dilutive to our shareholders. If we are unable to obtain adequate funds, we may be required to delay, scale-back or eliminate some of our manufacturing and marketing operations or we may need to obtain funds through arrangements on less favorable terms. Such circumstances raise doubt as to our ability to continue as a going concern. If we obtain funding on unfavorable terms, we may be required to relinquish rights to some of our intellectual property.

(12) Business Segmentation and Geographical Distribution   Revenue from international sources approximated $1,285 and $304 for the three months ended March 31, 2021 and 2020, respectively. All this revenue was product revenue.   Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue streams into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence®. The revenues for the three months ended March 31, 2021 and 2020, respectively, by category, are as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font-weight: bold">Product Category</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: left">Personal Care Ingredients</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,395</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,932</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Advanced Materials</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,378</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">584</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Solésence®</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4,299</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,523</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left">Total Revenue</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,072</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4,039</td></tr> </table>

The revenues for the three months ended March 31, 2021 and 2020, respectively, by category, are as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font-weight: bold">Product Category</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: left">Personal Care Ingredients</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,395</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">1,932</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Advanced Materials</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,378</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">584</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Solésence®</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4,299</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,523</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left">Total Revenue</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,072</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4,039</td></tr></table>

Quantitative information regarding the Company’s leases is as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended March 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended March 31, 2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Components of lease cost</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Finance lease cost components:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 0.125in">  Amortization of finance lease assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">  Interest on finance lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">  Total finance lease costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Operating lease cost components:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">  Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">144</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">140</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">  Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">  Short-term lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">    Total operating lease costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">185</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">169</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">205</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">197</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Supplemental cash flow information related to leases is as follows for the period ended March 31:    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="text-align: center; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">        Operating cash outflow from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">183</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">171</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average remaining lease term-finance leases (in years)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average remaining lease term-operating leases (in years)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average discount rate-finance leases</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10.1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average discount rate-operating leases</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr></table>

(9) Leases   The Company's operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company's leases include one or more options to renew or terminate the lease at the Company's discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term.   As of March 31, 2021, the operating lease right-of-use “ROU” asset had a balance of $1,886 which is included in the “Operating lease right-of-use assets” line item of these condensed consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $477 and $1,656, respectively. As of December 31, 2020, the ROU asset had a balance of $1,827 which is included in the “Operating lease right-of-use assets” line item of these condensed consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $431 and $1,651, respectively. These are included in the “Current portion of operating lease obligations” and “Long-term operating lease obligations, net of current portion” line items of these condensed consolidated financial statements. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.   The office leases contain variable lease payments which consist primarily of rent escalations based on an established index or rate and taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor.   Quantitative information regarding the Company’s leases is as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended March 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended March 31, 2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Components of lease cost</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Finance lease cost components:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 0.125in">  Amortization of finance lease assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">  Interest on finance lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">  Total finance lease costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Operating lease cost components:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">  Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">144</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">140</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">  Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">  Short-term lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">    Total operating lease costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">185</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">169</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">205</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">197</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Supplemental cash flow information related to leases is as follows for the period ended March 31:    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="text-align: center; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">        Operating cash outflow from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">183</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">171</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average remaining lease term-finance leases (in years)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average remaining lease term-operating leases (in years)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average discount rate-finance leases</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10.1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average discount rate-operating leases</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> </table>   The future maturities of the Company’s finance and operating leases as of March 31, 2021 is as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; text-align: left">2021</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">144</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">559</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">703</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">761</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">870</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">752</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">636</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">636</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026 and thereafter</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total payments</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">258</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,005</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less amounts representing interest</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(17</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(614</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(631</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum payments required:</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,133</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,374</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The future maturities of the Company’s finance and operating leases as of March 31, 2020 were as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Finance Leases</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Operating Leases</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: left">2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">189</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">506</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">695</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2021</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">196</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">687</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">109</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">705</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">814</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2023</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">690</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">695</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">580</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">580</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025 and thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total payments</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">499</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,168</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less amounts representing interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(51</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(862</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(913</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total minimum payments required:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">448</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,306</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,754</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

EX-101.CAL 6 nanx-20210331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 nanx-20210331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 nanx-20210331_lab.xml XBRL LABEL FILE Product and Service [Axis] Product Revenue [Member] Other Revenue [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Award Type [Axis] Stock Options [Member] Supply Commitment [Axis] BASF [Member] Range [Axis] Greater than [Member] Less than [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] Customer Four [Member] Customer Five [Member] Personal Care Ingredients [Member] Geographical [Axis] International Sources [Member] Advanced Materials [Member] Solesence [Member] Customer Three [Member] Customer One [Member] Customer Two [Member] Short-term Debt, Type [Axis] Line of Credit [Member] Type of Arrangement and Non-arrangement Transactions [Axis] New Business Loan Agreement [Member] Business Loan Agreement [Member] Credit Facility [Axis] Asset-Based Revolving Loan Facility [Member] Counterparty Name [Axis] Beachcorp, LLC [Member] Term Loan [Member] Letter of Credit [Member] First Amendment [Member] Term Loan and The Revolver Facility [Member] Long-term Debt, Type [Axis] 2% Secured Convertible Promissory Note Due on May 15, 2024 [Member] Related Party [Axis] Bradford T. Whitmore [Member] Related Party Credit Facilities [Member] Second Amendment [Member] Third Amendment [Member] Fourth Amendment [Member] Promissory Note (PPP) [Member] Libertyville [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Document Period End Date Entity File Number Entity Incorporation, State Code Current Fiscal Year End Date Entity Reporting Status Current Entity Interactive Data Current Entity Small Business Entity Filer Category Entity Emerging Growth Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Trade accounts receivable, less allowance for doubtful accounts of $9 for both March 31, 2021 and December 31, 2020 Inventories, net Prepaid expenses and other current assets Total current assets Equipment and leasehold improvements, net Operating leases, right of use Other assets, net Total assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Line of credit, bank Line of credit, related party Current portion of long-term debt, related party Current portion of finance lease obligations Current portion of operating lease obligations Accounts payable Deferred revenue Accrued expenses Total current liabilities Long-term portion of finance lease obligations Long-term portion of operating lease obligations Long-term convertible loan, related party PPP Loan (SBA) Asset retirement obligations Total long-term liabilities Contingent liabilities Shareholders' equity: Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding Common stock, $.01 par value, 55,000,000 shares authorized; 38,221,292 shares issued and outstanding on March 31, 2021 and December 31, 2020, respectively Additional paid-in capital Accumulated deficit Total Shareholders' equity Total liabilities and stockholders' equity Allowance for doubtful accounts Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Statement [Table] Statement [Line Items] Revenue: Total revenue Cost of revenue Gross profit Operating expense: Research and development expense Selling, general and administrative expense Income (loss) from operations Interest expense Income (loss) before provision for income taxes Provisions for income taxes Net Income (loss) Net income (loss) per share - basic (in dollars per share) Weighted average number of basic shares outstanding (in shares) Net income (loss) per share - diluted (in dollars per share) Weighted average number of diluted shares outstanding (in shares) Increase (Decrease) in Shareholders' Equity [Roll Forward] Balance at beginning Balance at beginning (in shares) Stock-based compensation Net income (loss) Balance at ending Balance at ending (in shares) Statement of Cash Flows [Abstract] Operating activities: Net Income (loss) Adjustments to reconcile net income (loss) to cash used in operating activities: Depreciation and amortization Amortization of debt discount Share-based compensation Changes in assets and liabilities related to operations: Trade accounts receivable Inventories Prepaid expenses and other assets Accounts payable Accrued expenses Deferred revenue Other long-term assets and liabilities Net cash used in operating activities Investing activities: Acquisition of equipment and leasehold improvements Net cash used in investing activities Financing activities: Principal payments on finance leases Proceeds from line of credit, bank Payments to line of credit, bank Proceeds from line of credit, related party Payments to line of credit, related party Net cash provided by financing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental cash flow information: Interest paid Supplemental non-cash investing and financing activities: Accounts payable incurred for the purchase of equipment and leasehold improvements Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Customers Two [Member] Going Concern / Liquidity New Business Loan Agreement [Member] Description of Business Revenue from Contract with Customer [Abstract] Revenues Earnings Per Share [Abstract] Earnings Per Share Fair Value Disclosures [Abstract] Financial Instruments Debt Disclosure [Abstract] Notes and Lines of Credit Inventory Disclosure [Abstract] Inventories Leases [Abstract] Leases Share-based Payment Arrangement [Abstract] EX-101.PRE 9 nanx-20210331_pre.xml XBRL PRESENTATION FILE EX-101.SCH 10 nanx-20210331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern / Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Notes and Line of Credit link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant Customers and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Business Segmentation and Geographical Distribution link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Business Segmentation and Geographical Distribution (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Earnings Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Notes and Line of Credit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Leases (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Leases (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Significant Customers and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Business Segmentation and Geographical Distribution (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) link:presentationLink link:calculationLink link:definitionLink XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2021	May 17, 2021
Cover [Abstract]
Entity Registrant Name	NANOPHASE TECHNOLOGIES Corp
Entity Central Index Key	0000883107
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Entity File Number	000-22333
Entity Incorporation, State Code	DE
Current Fiscal Year End Date	--12-31
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		48,336,877
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 1,819	$ 957
Trade accounts receivable, less allowance for doubtful accounts of $9 for both March 31, 2021 and December 31, 2020	3,828	2,932
Inventories, net	5,001	4,340
Prepaid expenses and other current assets	653	606
Total current assets	11,301	8,835
Equipment and leasehold improvements, net	3,004	2,868
Operating leases, right of use	1,886	1,827
Other assets, net	10	10
Total assets	16,201	13,540
Current liabilities:
Line of credit, bank	500	500
Line of credit, related party	3,365	2,155
Current portion of long-term debt, related party	500	500
Current portion of finance lease obligations	168	177
Current portion of operating lease obligations	477	431
Accounts payable	2,448	2,126
Deferred revenue	495	411
Accrued expenses	1,055	484
Total current liabilities	9,008	6,784
Long-term portion of finance lease obligations	73	110
Long-term portion of operating lease obligations	1,656	1,651
Long-term convertible loan, related party	1,164	1,097
PPP Loan (SBA)	952	952
Asset retirement obligations	216	214
Total long-term liabilities	4,061	4,024
Contingent liabilities
Shareholders' equity:
Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding
Common stock, $.01 par value, 55,000,000 shares authorized; 38,221,292 shares issued and outstanding on March 31, 2021 and December 31, 2020, respectively	382	382
Additional paid-in capital	102,159	102,117
Accumulated deficit	(99,409)	(99,767)
Total Shareholders' equity	3,132	2,732
Total liabilities and stockholders' equity	$ 16,201	$ 13,540

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 9	$ 9
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized	24,088	24,088
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	55,000,000	55,000,000
Common stock, issued	38,221,292	38,221,292
Common stock, outstanding	38,221,292	38,221,292

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue:
Total revenue	$ 7,072	$ 4,039
Cost of revenue	5,042	3,005
Gross profit	2,030	1,034
Operating expense:
Research and development expense	499	372
Selling, general and administrative expense	1,034	705
Income (loss) from operations	497	(43)
Interest expense	139	124
Income (loss) before provision for income taxes	358	(167)
Provisions for income taxes
Net Income (loss)	$ 358	$ (167)
Net income (loss) per share - basic (in dollars per share)	$ 0.01	$ (0.00)
Weighted average number of basic shares outstanding (in shares)	38,221,292	38,136,792
Net income (loss) per share - diluted (in dollars per share)	$ 0.01	$ (0.00)
Weighted average number of diluted shares outstanding (in shares)	39,811,292	38,136,792
Product Revenue [Member]
Revenue:
Total revenue	$ 7,050	$ 3,961
Other Revenue [Member]
Revenue:
Total revenue	$ 22	$ 78

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (Unaudited Consolidated Condensed) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at beginning at Dec. 31, 2019	$ 381	$ 101,886	$ (100,756)	$ 1,511
Balance at beginning (in shares) at Dec. 31, 2019	38,136,792
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Stock-based compensation		52		52
Net income (loss)			(167)	(167)
Balance at ending at Mar. 31, 2020	$ 381	101,938	(100,923)	1,396
Balance at ending (in shares) at Mar. 31, 2020	38,136,792
Balance at beginning at Dec. 31, 2020	$ 382	102,117	(99,767)	2,732
Balance at beginning (in shares) at Dec. 31, 2020	38,221,292
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Stock-based compensation		42		42
Net income (loss)			358	358
Balance at ending at Mar. 31, 2021	$ 382	$ 102,159	$ (99,409)	$ 3,132
Balance at ending (in shares) at Mar. 31, 2021	38,221,292

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating activities:
Net Income (loss)	$ 358	$ (167)
Adjustments to reconcile net income (loss) to cash used in operating activities:
Depreciation and amortization	101	86
Amortization of debt discount	67	67
Share-based compensation	42	52
Changes in assets and liabilities related to operations:
Trade accounts receivable	(896)	(1,284)
Inventories	(661)	170
Prepaid expenses and other assets	(47)	8
Accounts payable	253	(35)
Accrued expenses	571	133
Deferred revenue	84	(207)
Other long-term assets and liabilities	(9)	(3)
Net cash used in operating activities	(137)	(1,180)
Investing activities:
Acquisition of equipment and leasehold improvements	(166)	(181)
Net cash used in investing activities	(166)	(181)
Financing activities:
Principal payments on finance leases	(46)	(58)
Proceeds from line of credit, bank	500	500
Payments to line of credit, bank	(500)	(500)
Proceeds from line of credit, related party	6,500	3,260
Payments to line of credit, related party	(5,289)	(2,084)
Net cash provided by financing activities	1,165	1,118
Increase (decrease) in cash and cash equivalents	862	(243)
Cash and cash equivalents at beginning of period	957	1,194
Cash and cash equivalents at end of period	1,819	951
Supplemental cash flow information:
Interest paid	51	57
Supplemental non-cash investing and financing activities:
Accounts payable incurred for the purchase of equipment and leasehold improvements	$ 69	$ 77

XML 17 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

3 Months Ended

Mar. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

(1) Basis of Presentation

XML 18 R8.htm IDEA: XBRL DOCUMENT

Going Concern / Liquidity

3 Months Ended

Mar. 31, 2021

Customers Two [Member]

Going Concern / Liquidity

(2)

Going Concern / Liquidity

XML 19 R9.htm IDEA: XBRL DOCUMENT

Description of Business

3 Months Ended

Mar. 31, 2021

Description Of Business Abstract

Description of Business

(3) Description of Business

XML 20 R10.htm IDEA: XBRL DOCUMENT

Revenues

3 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenues

(4) Revenues

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Earnings Per Share

3 Months Ended

Mar. 31, 2021

Earnings Per Share [Abstract]

Earnings Per Share

(5) Earnings Per Share

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

	Three Months Ended March 31,
	2021		2020
Numerator: (in Thousands)
Net income (loss)	$	358	$	(167	)

Denominator:
Weighted average number of basic common shares outstanding		38,221,292		38,136,792
Weighted average additional shares assuming conversion of in-the-money stock options to common shares		1,590,000		—
Weighted average number of diluted common shares outstanding		39,811,292		38,136,792

Basic earnings per common share:
Net income (loss) per share – basic	$	0.01	$	(0.00	)
Diluted earnings per common share:
Net income (loss) per share – diluted	$	0.01	$	(0.00	)

XML 22 R12.htm IDEA: XBRL DOCUMENT

Financial Instruments

3 Months Ended

Mar. 31, 2021

Fair Value Disclosures [Abstract]

Financial Instruments

(6) Financial Instruments

There were no financial instruments adjusted to fair value on March 31, 2021 and December 31, 2020.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Notes and Line of Credit

3 Months Ended

Mar. 31, 2021

Debt Disclosure [Abstract]

Notes and Lines of Credit

(7) Notes and Line of Credit

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2021

Inventory Disclosure [Abstract]

Inventories

(8) Inventories

Inventories consist of the following:

	March 31, 2021			December 31, 2020
Raw materials	$	3,883		$	2,825
Finished goods		1,148			1,545
		5,031			4,370
Allowance for excess inventory quantities		(30	)		(30	)
	$	5,001		$	4,340

XML 25 R15.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Mar. 31, 2021

Leases [Abstract]

Leases

(9) Leases

Quantitative information regarding the Company’s leases is as follows:

	Three Months Ended March 31, 2021		Three Months Ended March 31, 2020
Components of lease cost
Finance lease cost components:
Amortization of finance lease assets	$	14	$	17
Interest on finance lease liabilities		6		11
Total finance lease costs		20		28
Operating lease cost components:
Operating lease cost		144		140
Variable lease cost		31		27
Short-term lease cost		10		2
Total operating lease costs		185		169

Total lease cost	$	205	$	197

Supplemental cash flow information related to leases is as follows for the period ended March 31:

	2021			2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflow from operating leases	$	183		$	171

Weighted-average remaining lease term-finance leases (in years)		1.3			1.7
Weighted-average remaining lease term-operating leases (in years)		3.1			2.7
Weighted-average discount rate-finance leases		10.1	%		9.3	%
Weighted-average discount rate-operating leases		14.2	%		14.6	%

The future maturities of the Company’s finance and operating leases as of March 31, 2021 is as follows:

	Finance Leases			Operating Leases			Total
2021	$	144		$	559		$	703
2022		109			761			870
2023		5			747			752
2024		—			636			636
2025		—			42			42
2026 and thereafter		—			2			2
Total payments	$	258		$	2,747		$	3,005
Less amounts representing interest		(17	)		(614	)		(631	)
Total minimum payments required:	$	241		$	2,133		$	2,374

The future maturities of the Company’s finance and operating leases as of March 31, 2020 were as follows:

	Finance Leases			Operating Leases			Total
2020	$	189		$	506		$	695
2021		196			687			883
2022		109			705			814
2023		5			690			695
2024		—			580			580
2025 and thereafter		—			—			—
Total payments	$	499		$	3,168		$	3,667
Less amounts representing interest		(51	)		(862	)		(913	)
Total minimum payments required:	$	448		$	2,306		$	2,754

XML 26 R16.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

(10) Share-Based Compensation

Stock Options and Stock Grants

XML 27 R17.htm IDEA: XBRL DOCUMENT

Significant Customers and Contingencies

3 Months Ended

Mar. 31, 2021

Risks and Uncertainties [Abstract]

Significant Customers and Contingencies

(11) Significant Customers and Contingencies

XML 28 R18.htm IDEA: XBRL DOCUMENT

Business Segmentation and Geographical Distribution

3 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Business Segmentation and Geographical Distribution

(12) Business Segmentation and Geographical Distribution

Revenue from international sources approximated $1,285 and $304 for the three months ended March 31, 2021 and 2020, respectively. All this revenue was product revenue.

Product Category	2021		2020
Personal Care Ingredients	$	1,395	$	1,932
Advanced Materials		1,378		584
Solésence^®		4,299		1,523
Total Revenue	$	7,072	$	4,039

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2021

Earnings Per Share [Abstract]

Schedule of earnings per share

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

	Three Months Ended March 31,
	2021		2020
Numerator: (in Thousands)
Net income (loss)	$	358	$	(167	)

Denominator:
Weighted average number of basic common shares outstanding		38,221,292		38,136,792
Weighted average additional shares assuming conversion of in-the-money stock options to common shares		1,590,000		—
Weighted average number of diluted common shares outstanding		39,811,292		38,136,792

Basic earnings per common share:
Net income (loss) per share – basic	$	0.01	$	(0.00	)
Diluted earnings per common share:
Net income (loss) per share – diluted	$	0.01	$	(0.00	)

XML 30 R20.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

3 Months Ended

Mar. 31, 2021

Inventory Disclosure [Abstract]

Schedule of inventories

Inventories consist of the following:

	March 31, 2021			December 31, 2020
Raw materials	$	3,883		$	2,825
Finished goods		1,148			1,545
		5,031			4,370
Allowance for excess inventory quantities		(30	)		(30	)
	$	5,001		$	4,340

XML 31 R21.htm IDEA: XBRL DOCUMENT

Lease (Tables)

3 Months Ended

Mar. 31, 2021

Leases [Abstract]

Summary of quantitative information about leases

Quantitative information regarding the Company’s leases is as follows:

	Three Months Ended March 31, 2021		Three Months Ended March 31, 2020
Components of lease cost
Finance lease cost components:
Amortization of finance lease assets	$	14	$	17
Interest on finance lease liabilities		6		11
Total finance lease costs		20		28
Operating lease cost components:
Operating lease cost		144		140
Variable lease cost		31		27
Short-term lease cost		10		2
Total operating lease costs		185		169

Total lease cost	$	205	$	197

Summary of supplemental cash flow information related to leases

Supplemental cash flow information related to leases is as follows for the period ended March 31:

	2021			2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflow from operating leases	$	183		$	171

Weighted-average remaining lease term-finance leases (in years)		1.3			1.7
Weighted-average remaining lease term-operating leases (in years)		3.1			2.7
Weighted-average discount rate-finance leases		10.1	%		9.3	%
Weighted-average discount rate-operating leases		14.2	%		14.6	%

Schedule of future maturities of finance and operating leases

The future maturities of the Company’s finance and operating leases as of March 31, 2021 is as follows:

	Finance Leases			Operating Leases			Total
2021	$	144		$	559		$	703
2022		109			761			870
2023		5			747			752
2024		—			636			636
2025		—			42			42
2026 and thereafter		—			2			2
Total payments	$	258		$	2,747		$	3,005
Less amounts representing interest		(17	)		(614	)		(631	)
Total minimum payments required:	$	241		$	2,133		$	2,374

The future maturities of the Company’s finance and operating leases as of March 31, 2020 were as follows:

	Finance Leases			Operating Leases			Total
2020	$	189		$	506		$	695
2021		196			687			883
2022		109			705			814
2023		5			690			695
2024		—			580			580
2025 and thereafter		—			—			—
Total payments	$	499		$	3,168		$	3,667
Less amounts representing interest		(51	)		(862	)		(913	)
Total minimum payments required:	$	448		$	2,306		$	2,754

XML 32 R22.htm IDEA: XBRL DOCUMENT

Business Segmentation and Geographical Distribution (Tables)

3 Months Ended

Mar. 31, 2021

Segments, Geographical Areas [Abstract]

Schedule of revenue by category

The revenues for the three months ended March 31, 2021 and 2020, respectively, by category, are as follows:

Product Category	2021		2020
Personal Care Ingredients	$	1,395	$	1,932
Advanced Materials		1,378		584
Solésence^®		4,299		1,523
Total Revenue	$	7,072	$	4,039

XML 33 R23.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Numerator: (in Thousands)
Net income (loss)	$ 358	$ (167)
Denominator:
Weighted average number of basic common shares outstanding	38,221,292	38,136,792
Weighted average additional shares assuming conversion of in-the-money stock options to common shares	1,590,000
Weighted average number of diluted common shares outstanding	39,811,292	38,136,792
Basic earnings per common share:
Net income (loss) per share - basic	$ 0.01	$ (0.00)
Diluted earnings per common share:
Net income (loss) per share - diluted	$ 0.01	$ (0.00)

XML 34 R24.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Details Narrative) - shares	3 Months Ended
Earnings Per Share (Details Narrative) - shares	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Options included in computation of earnings per share	1,590,000
Anti-dilutive securities excluded from computation of earnings per share		1,000

XML 35 R25.htm IDEA: XBRL DOCUMENT

Notes and Line of Credit (Details Narrative) $ / shares in Units, $ in Thousands							1 Months Ended	3 Months Ended
	Apr. 21, 2021 USD ($)	Apr. 17, 2020 USD ($)	Mar. 23, 2020	Nov. 20, 2019 USD ($) $ / shares	Mar. 22, 2019 USD ($) Number	Nov. 16, 2018 USD ($)	Jul. 31, 2014 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 23, 2020 USD ($)	Sep. 08, 2020 USD ($)
Interest expense								$ 139	$ 124
2% Secured Convertible Promissory Note Due on May 15, 2024 [Member] \| Bradford T. Whitmore [Member]
Principal amount				$ 2,000
Fixed annual interest rate				2.00%
Payment frequency				interest is payable semi-annually on the 15th day of May and November
Date of first payment				May 15, 2020
Debt conversion price (in dollars per share) \| $ / shares				$ 0.20
Share price (in dollars per share) \| $ / shares				$ 0.32
Debt discount				$ 1,200				836		$ 903
Principal balance								1,164		$ 1,097
Debt balance								2,000
Promissory Note (PPP) [Member] \| Libertyville [Member]
Principal amount		$ 952
Fixed annual interest rate		1.00%
Payment frequency		eighteen equal monthly installments
Date of first payment		Nov. 17, 2020
Debt balance		$ 952
Term Loan [Member] \| Beachcorp, LLC [Member]
Debt balance								500
Asset-Based Revolving Loan Facility [Member] \| Beachcorp, LLC [Member]
Debt balance								3,365
Related Party Credit Facilities [Member]
Interest expense								131	111
Accrued interest expense								36	$ 20
Available borrowing amount								$ 388
Business Loan Agreement [Member] \| Term Loan [Member] \| Beachcorp, LLC [Member]
Maximum borrowing capacity						$ 500
Fixed annual interest rate						8.25%
Maturity date						Dec. 31, 2020
Ownership percentage						63.00%
Business Loan Agreement [Member] \| Asset-Based Revolving Loan Facility [Member] \| Beachcorp, LLC [Member]
Basis spread variable interest rate						3.00%
Variable interest rate basis						Prime rate
Maximum borrowing capacity						$ 2,000
Facility, expiration date						Mar. 31, 2020
Business Loan Agreement [Member] \| Asset-Based Revolving Loan Facility [Member] \| Beachcorp, LLC [Member] \| Greater than [Member]
Fixed annual interest rate						8.25%
First Amendment [Member] \| Term Loan and The Revolver Facility [Member] \| Beachcorp, LLC [Member]
Maturity date			Mar. 31, 2021
Second Amendment [Member] \| Asset-Based Revolving Loan Facility [Member] \| Beachcorp, LLC [Member]
Maximum borrowing capacity												$ 2,750
Third Amendment [Member] \| Asset-Based Revolving Loan Facility [Member] \| Beachcorp, LLC [Member]
Maximum borrowing capacity											$ 4,000
Fourth Amendment [Member] \| Term Loan [Member] \| Beachcorp, LLC [Member]
Maximum borrowing capacity	$ 1,000
Fixed annual interest rate	5.25%
Maturity date	Mar. 31, 2022
Fourth Amendment [Member] \| Asset-Based Revolving Loan Facility [Member] \| Beachcorp, LLC [Member]
Basis spread variable interest rate	2.00%
Variable interest rate basis	Prime rate
Maximum borrowing capacity	$ 6,000
Facility, expiration date	Mar. 31, 2023
Letter of Credit [Member]
Letter of credit and related promissory note							$ 30
Basis spread variable interest rate							1.00%
Variable interest rate basis							Prime rate
Line of Credit [Member] \| New Business Loan Agreement [Member]
Basis spread variable interest rate					1.00%
Variable interest rate basis					Prime rate
Maximum borrowing capacity					$ 500
Borrowing capacity as percentage of accounts receivable					75.00%
Borrowing capacity as multiple of accounts receivable \| Number					2
Minimum amount of cash on hand before advance is given					$ 500
Facility, expiration date					May 04, 2021

XML 36 R26.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 3,883	$ 2,825
Finished goods	1,148	1,545
Total inventory, gross	5,031	4,370
Allowance for excess inventory quantities	(30)	(30)
Total inventory	$ 5,001	$ 4,340

XML 37 R27.htm IDEA: XBRL DOCUMENT

Leases (Details) - USD ($) $ in Thousands	3 Months Ended
Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Finance lease cost components:
Amortization of finance lease assets	$ 14	$ 17
Interest on finance lease liabilities	6	11
Total finance lease costs	20	28
Operating lease cost components:
Operating lease cost	144	140
Variable lease cost	31	27
Short-term lease cost	10	2
Total operating lease costs	185	169
Total lease cost	$ 205	$ 197

XML 38 R28.htm IDEA: XBRL DOCUMENT

Leases (Details 1) - USD ($) $ in Thousands	3 Months Ended
Leases (Details 1) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Cash paid for amounts included in the measurement of lease liabiltiies:
Operating cash outflow from operating leases	$ 183	$ 171
Weighted-average remaining lease term-finance leases (in years)	1 year 3 months 19 days	1 year 8 months 12 days
Weighted-average remaining lease term-operating leases (in years)	3 years 1 month 6 days	2 years 8 months 12 days
Weighted-average discount rate-finance leases	10.10%	9.30%
Weighted-average discount rate-operating leases	14.20%	14.60%

XML 39 R29.htm IDEA: XBRL DOCUMENT

Leases (Details 2) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Finance Leases:
Year 1	$ 144	$ 189
Year 2	109	196
Year 3	5	109
Year 4		5
Total payments	258	499
Less amounts representing interest	(17)	(51)
Total minimum payments required:	241	448
Operating Leases:
Year 1	559	506
Year 2	761	687
Year 3	747	705
Year 4	636	690
Year 5	42	580
Thereafter	2
Total payments	2,747	3,168
Less amounts representing interest	(614)	(862)
Total minimum payments required:	2,133	2,306
Total:
Year 1	703	695
Year 2	870	883
Year 3	752	814
Year 4	636	695
Year 5	42	580
Thereafter	2
Total payments	3,005	3,667
Less amounts representing interest	(631)	(913)
Total minimum payments required:	$ 2,374	$ 2,754

XML 40 R30.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease right-of-use assets	$ 1,886	$ 1,827
Current portion of operating lease obligations	477	431
Long-term portion of operating lease obligations	$ 1,656	$ 1,651

XML 41 R31.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to nonvested share-based compensation arrangements granted	$ 206
Weighted-average period over which unrecognized compensation is expected to be recognized	1 year 8 months 12 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 42	$ 52
Stock options granted	0	0
Stock options excercise	0	0
Stock options expired	35,000	241,000
Stock options forfeited	0	140,000
Stock options outstanding, end of period	3,411,000	3,332,000
Weighted average exercise price	$ 0.57	$ 0.63

XML 42 R32.htm IDEA: XBRL DOCUMENT

Significant Customers and Contingencies (Details Narrative) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($) Number	Mar. 31, 2020 USD ($) Number	Dec. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)
Number of major customers \| Number	5	5
Accounts receivable	$ 3,828
Finished goods inventory	1,148		$ 1,545
Customer One [Member]
Accounts receivable	837	$ 0
Cash, cash equivalents and investments trigger under supply agreeement
Customer Two [Member]
Accounts receivable	812	896
Cash, cash equivalents and investments trigger under supply agreeement
Customer Three [Member]
Accounts receivable	476	31
Cash, cash equivalents and investments trigger under supply agreeement
Customer Four [Member]
Accounts receivable	855	180
Cash, cash equivalents and investments trigger under supply agreeement
Customer Five [Member]
Accounts receivable	$ 390	$ 593
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer One [Member]
Revenue from customers	24.00%	0.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer Two [Member]
Revenue from customers	20.00%	46.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer Three [Member]
Revenue from customers	17.00%	15.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer Four [Member]
Revenue from customers	15.00%	4.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer Five [Member]
Revenue from customers	10.00%	15.00%
BASF [Member]
Equipment sale - net book value equipment	115.00%
BASF [Member] \| Less than [Member]
Earnings trigger under supply agreeement	$ 0
Cash, cash equivalents and investments trigger under supply agreeement	500
BASF [Member] \| Greater than [Member]
Cash, cash equivalents and investments trigger under supply agreeement				$ 1,000
Accelerated debt maturity - principal amount debt	$ 10,000
Finished goods inventory				$ 500
Equipment sale - original book value of equipment and upgrades	30.00%

XML 43 R33.htm IDEA: XBRL DOCUMENT

Business Segmentation and Geographical Distribution (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Sales	$ 7,072	$ 4,039
Personal Care Ingredients [Member]
Sales	1,395	1,932
Advanced Materials [Member]
Sales	1,378	584
Solesence [Member]
Sales	$ 4,299	$ 1,523

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 44 R34.htm IDEA: XBRL DOCUMENT

Business Segmentation and Geographical Distribution (Details Narrative) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($) Number	Mar. 31, 2020 USD ($)
Number of business segments \| Number	1
International Sources [Member]
Revenue from international sources \| $	$ 1,285	$ 304

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 46 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 98 279 1 false 38 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://nanophase.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) Sheet http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (Unaudited Consolidated Condensed) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://nanophase.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern / Liquidity Sheet http://nanophase.com/role/GoingConcernLiquidity Going Concern / Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - Description of Business Sheet http://nanophase.com/role/DescriptionOfBusiness Description of Business Notes 9 false false R10.htm 00000010 - Disclosure - Revenues Sheet http://nanophase.com/role/Revenues Revenues Notes 10 false false R11.htm 00000011 - Disclosure - Earnings Per Share Sheet http://nanophase.com/role/EarningsPerShare Earnings Per Share Notes 11 false false R12.htm 00000012 - Disclosure - Financial Instruments Sheet http://nanophase.com/role/FinancialInstruments Financial Instruments Notes 12 false false R13.htm 00000013 - Disclosure - Notes and Line of Credit Notes http://nanophase.com/role/NotesAndLineOfCredit Notes and Line of Credit Notes 13 false false R14.htm 00000014 - Disclosure - Inventories Sheet http://nanophase.com/role/Inventories Inventories Notes 14 false false R15.htm 00000015 - Disclosure - Leases Sheet http://nanophase.com/role/Leases Leases Notes 15 false false R16.htm 00000016 - Disclosure - Share-Based Compensation Sheet http://nanophase.com/role/Share-basedCompensation Share-Based Compensation Notes 16 false false R17.htm 00000017 - Disclosure - Significant Customers and Contingencies Sheet http://nanophase.com/role/SignificantCustomersAndContingencies Significant Customers and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Business Segmentation and Geographical Distribution Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution Business Segmentation and Geographical Distribution Notes 18 false false R19.htm 00000019 - Disclosure - Earnings Per Share (Tables) Sheet http://nanophase.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://nanophase.com/role/EarningsPerShare 19 false false R20.htm 00000020 - Disclosure - Inventories (Tables) Sheet http://nanophase.com/role/InventoriesTables Inventories (Tables) Tables http://nanophase.com/role/Inventories 20 false false R21.htm 00000021 - Disclosure - Lease (Tables) Sheet http://nanophase.com/role/LeaseTables Lease (Tables) Tables http://nanophase.com/role/Leases 21 false false R22.htm 00000022 - Disclosure - Business Segmentation and Geographical Distribution (Tables) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables Business Segmentation and Geographical Distribution (Tables) Tables http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution 22 false false R23.htm 00000023 - Disclosure - Earnings Per Share (Details) Sheet http://nanophase.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://nanophase.com/role/EarningsPerShareTables 23 false false R24.htm 00000024 - Disclosure - Earnings Per Share (Details Narrative) Sheet http://nanophase.com/role/EarningsPerShareDetailsNarrative Earnings Per Share (Details Narrative) Details http://nanophase.com/role/EarningsPerShareTables 24 false false R25.htm 00000025 - Disclosure - Notes and Line of Credit (Details Narrative) Notes http://nanophase.com/role/NotesAndLineOfCreditDetailsNarrative Notes and Line of Credit (Details Narrative) Details http://nanophase.com/role/NotesAndLineOfCredit 25 false false R26.htm 00000026 - Disclosure - Inventories (Details) Sheet http://nanophase.com/role/InventoriesDetails Inventories (Details) Details http://nanophase.com/role/InventoriesTables 26 false false R27.htm 00000027 - Disclosure - Leases (Details) Sheet http://nanophase.com/role/LeasesDetails Leases (Details) Details http://nanophase.com/role/LeaseTables 27 false false R28.htm 00000028 - Disclosure - Leases (Details 1) Sheet http://nanophase.com/role/LeasesDetails1 Leases (Details 1) Details http://nanophase.com/role/LeaseTables 28 false false R29.htm 00000029 - Disclosure - Leases (Details 2) Sheet http://nanophase.com/role/LeasesDetails2 Leases (Details 2) Details http://nanophase.com/role/LeaseTables 29 false false R30.htm 00000030 - Disclosure - Leases (Details Narrative) Sheet http://nanophase.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://nanophase.com/role/LeaseTables 30 false false R31.htm 00000031 - Disclosure - Share-Based Compensation (Details Narrative) Sheet http://nanophase.com/role/Share-basedCompensationDetailsNarrative Share-Based Compensation (Details Narrative) Details http://nanophase.com/role/Share-basedCompensation 31 false false R32.htm 00000032 - Disclosure - Significant Customers and Contingencies (Details Narrative) Sheet http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative Significant Customers and Contingencies (Details Narrative) Details http://nanophase.com/role/SignificantCustomersAndContingencies 32 false false R33.htm 00000033 - Disclosure - Business Segmentation and Geographical Distribution (Details) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetails Business Segmentation and Geographical Distribution (Details) Details http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables 33 false false R34.htm 00000034 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative Business Segmentation and Geographical Distribution (Details Narrative) Details http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables 34 false false All Reports Book All Reports nanx-20210331.xml nanx-20210331.xsd nanx-20210331_cal.xml nanx-20210331_def.xml nanx-20210331_lab.xml nanx-20210331_pre.xml http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 true true ZIP 50 0001387131-21-005719-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-21-005719-xbrl.zip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Ì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end